<SEC-DOCUMENT>0001193125-20-316016.txt : 20201211
<SEC-HEADER>0001193125-20-316016.hdr.sgml : 20201211
<ACCEPTANCE-DATETIME>20201211172854
ACCESSION NUMBER:		0001193125-20-316016
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20201211
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201211
DATE AS OF CHANGE:		20201211

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		201384508

	BUSINESS ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d68225d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20201211" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2020-12-11_to_2020-12-11">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2020-12-11_to_2020-12-11">0001062822</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="lxrx-20201211.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2020-12-11_to_2020-12-11"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-11</xbrli:startDate> <xbrli:endDate>2020-12-11</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2020-12-11_to_2020-12-11">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2020-12-11_to_2020-12-11" format="ixt:datemonthdayyearen">December 11, 2020</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2020-12-11_to_2020-12-11">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2020-12-11_to_2020-12-11" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2020-12-11_to_2020-12-11">000-30111</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2020-12-11_to_2020-12-11">76-0474169</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction of</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">incorporation or organization)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification Number)</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2020-12-11_to_2020-12-11">8800 Technology Forest Place</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2020-12-11_to_2020-12-11">The Woodlands</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2020-12-11_to_2020-12-11" format="ixt-sec:stateprovnameen">Texas</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2020-12-11_to_2020-12-11">77381</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices and Zip Code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2020-12-11_to_2020-12-11">(281)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2020-12-11_to_2020-12-11">863-3000</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2020-12-11_to_2020-12-11">Common stock, par value $0.001</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2020-12-11_to_2020-12-11">LXRX</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2020-12-11_to_2020-12-11" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2020-12-11_to_2020-12-11" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2020-12-11_to_2020-12-11" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2020-12-11_to_2020-12-11" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2020-12-11_to_2020-12-11" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (17 CFR <span style="white-space:nowrap">&#167;240.12b-2).</span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2020-12-11_to_2020-12-11" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December 11, 2020, Lexicon Pharmaceuticals, Inc. (the &#8220;Company&#8221;) entered into a Subscription Agreement (the &#8220;Subscription Agreement&#8221;) with certain institutional investors identified on the signature pages thereto (the &#8220;Purchasers&#8221;), pursuant to which the Company agreed to issue and sell, and the Purchasers agreed to purchase and acquire, 20,312,500&#160;shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Shares&#8221;), in a registered direct offering (the &#8220;Offering&#8221;). The investors in the Offering were Artal International S.C.A., an affiliate of Invus, L.P., the Company&#8217;s largest stockholder, and BVF Partners L.P. and certain affiliates of BVF Partners L.P. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Shares were offered at a purchase price of $3.20 per share, and the aggregate gross proceeds to the Company from the Offering are expected to be approximately $65.0 million, before deducting certain fees and expenses related to the Offering and payable by the Company, including the Offering Fees (as defined below). The Offering is expected to close on or about December&#160;16, 2020, subject to customary closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Subscription Agreement, the Company has agreed to take all necessary steps to (i)&#160;include and recommend the Charter Amendment (as defined below) in the proxy statement to be sent to stockholders in advance of the Company&#8217;s next annual meeting of stockholders (and subsequent meetings of stockholders, if necessary), and (ii)&#160;solicit from eligible stockholders (including, if necessary, prior to subsequent meetings) proxies in favor of the Charter Amendment. &#8220;Charter Amendment&#8221; shall mean an Amendment to the Company&#8217;s Certificate of Incorporation that grants holders of 20% or more of the Company&#8217;s issued and outstanding common stock (i)&#160;customary pre-emptive rights and (ii)&#160;consent rights prior to the Company taking any of the following actions (x)&#160;creating or issuing any new class or series of shares of capital stock of the Company (or securities convertible into or exercisable for shares of capital stock of the Company) having rights, preferences or privileges senior to or on parity with the common stock, (y)&#160;subject to certain exceptions, repurchasing, retiring, redeeming or otherwise acquiring any equity securities (or securities convertible into or exchangeable for equity securities) of the Company or any subsidiary and (z)&#160;adopting, or proposing to adopt, or maintaining any shareholders&#8217; rights plan, &#8220;poison pill&#8221; or other similar plan or agreement, unless such stockholder is exempt from such plan or agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Subscription Agreements contain representations, warranties and other provisions customary for transactions of this nature. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Offering, the Company also entered into a Placement Agency Agreement, dated as of December 11, 2020 (the &#8220;Placement Agency Agreement&#8221;), with Citigroup Global Markets acting as placement agent (the &#8220;Placement Agent&#8221;) for the Company, on a &#8220;reasonable best efforts&#8221; basis. Pursuant to the Placement Agency Agreement, upon and subject to the closing of the Offering, the Company will pay to the Placement Agent a cash fee equals to six percent (6%) of the gross proceeds raised in the Offering; provided that no fee will be paid on the gross proceeds received from any Shares purchased by Invus L.P. or its affiliates (the &#8220;Offering Fees&#8221;). The Company has also agreed to reimburse the Placement Agent for certain expenses incurred by the Placement Agent in connection with the Offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Shares described above are being offered by the Company pursuant to a &#8220;shelf&#8221; registration statement on Form <span style="white-space:nowrap">S-3,</span> which was originally filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on November&#160;7, 2019, and was declared effective on November&#160;18, 2019 (File <span style="white-space:nowrap">No.&#160;333-234568)</span> (the &#8220;Registration Statement&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summaries of the Offering, the Shares, the Subscription Agreement and the Placement Agency Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the definitive transaction documents. Copies of the Subscription Agreement and the Placement Agency Agreement are attached hereto as Exhibits 10.1 and 10.2, respectively, and are incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December 11, 2020, the Company issued a press release announcing the Offering, a copy of which is attached hereto as Exhibit 99.1. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Vinson&#160;&amp; Elkins L.L.P., our counsel, has issued a legal opinion relating to the validity of the Shares being offered pursuant to the Subscription Agreement. A copy of such legal opinion, including the consent included therein, is filed as Exhibit 5.1 to this current report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the transaction described above, the Company updated the description of its business and its risk factors in the disclosures provided to investors. The updated description of the Company&#8217;s business is set forth in Exhibit 99.2 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated by reference herein. The updated description of the Company&#8217;s risk factors provided to investors in the Offering is set forth in Exhibit 99.3 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated by reference herein. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:90%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:91%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;text-align:center">Exhibit<br />Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d68225dex51.htm">Opinion of Vinson&#160;&amp; Elkins L.L.P. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d68225dex101.htm">Subscription Agreement </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d68225dex102.htm">Placement Agency Agreement </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d68225dex51.htm">Consent of Vinson &amp; Elkins L.L.P. (included in Exhibit 5.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d68225dex991.htm">Press Release dated December 11, 2020. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d68225dex992.htm">Business Description. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d68225dex993.htm">Risk Factors. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">EX-104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Signatures </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Lexicon Pharmaceuticals, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: December 11, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ BRIAN T. CRUM</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Brian T. Crum</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><span style="font-style:italic">Vice President and General Counsel</span></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d68225dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g68225dsp1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;11, 2020 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">800 Technology Forest Place </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Woodlands, TX 77381 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel for Lexicon Pharmaceuticals, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), with respect to certain
legal matters in connection with the proposed issuance and sale by the Company of 20,312,500 shares (the &#147;<U>Shares</U>&#148;) of common stock, par value $0.001 (the &#147;<U>Common Stock</U>&#148;), pursuant to that certain Subscription
Agreement, dated December&nbsp;11, 2020 (the &#147;<U>Subscription Agreement</U>&#148;) between the Company and the purchasers named therein. We have participated in the preparation of a Prospectus Supplement dated December&nbsp;11, 2020 (the
&#147;<U>Prospectus Supplement</U>&#148;), forming part of the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> effective as of November&nbsp;18, 2019 (the &#147;<U>Registration Statement</U>&#148;), that also contains a
base prospectus (the &#147;<U>Base Prospectus</U>&#148; and, together with the Prospectus Supplement, the &#147;<U>Prospectus</U>&#148;). The Prospectus Supplement has been filed pursuant to Rule 424(b) promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In rendering the opinions set forth below, we have examined and relied upon (i)&nbsp;the Registration Statement and the Prospectus;
(ii)&nbsp;the Amended and Restated Certificate of Incorporation of the Company, as amended to the date hereof; (iii)&nbsp;the Second Amended and Restated Bylaws of the Company, as amended to the date hereof; (iv)&nbsp;the Subscription Agreement;
(v)&nbsp;resolutions of the Board of Directors of the Company dated December&nbsp;11, 2020; and (vi)&nbsp;such other certificates and other instruments and documents as we consider appropriate for purposes of the opinions hereafter expressed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have assumed that all Shares will be issued and sold in the manner stated in the Prospectus and the
Subscription Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the foregoing and subject to the assumptions, exceptions, limitations and qualifications set forth
below, we are of the opinion that the Shares, when issued and delivered against payment therefore in accordance with the Subscription Agreement, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> except as
described in the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinions expressed herein are qualified in the following respects: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. We have assumed that (i)&nbsp;each document submitted to us for review is accurate and complete, each such document that is an original is
authentic, each such document that is a copy conforms to an authentic original and all signatures on each such document are genuine, and (ii)&nbsp;each certificate from governmental officials reviewed by us is accurate, complete and authentic, and
all official public records are accurate and complete. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vinson&nbsp;&amp; Elkins LLP Attorneys at Law</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austin Dallas Dubai Houston London New York</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Richmond Riyadh San
Francisco Tokyo Washington</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1001 Fannin Street, Suite 2500</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Houston, TX
77002-6760</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Tel</B> +1.713.758.2222 <B>Fax</B> +1.713.758.2346 <B>velaw.com</B></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g68225dsp1a.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">December 11, 2020 Page 2</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. This opinion is limited in all respects to the federal laws of the United States, the
Delaware General Corporation Law and the Constitution of the State of Delaware, as interpreted by the courts of the State of Delaware and of the United States. We are expressing no opinion as to the effect of the laws of any other jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion as Exhibit 5.1 to the Company&#146;s Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> dated on or about the date hereof, to the incorporation by reference of this opinion into the Registration Statement and to the reference to our Firm under the caption &#147;Legal Matters&#148; in the
Prospectus forming a part of the Registration Statement. In giving this consent, we do not hereby admit that we are within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations of
the Commission thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Vinson&nbsp;&amp; Elkins L.L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Vinson&nbsp;&amp; Elkins L.L.P.</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>d68225dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Execution Version</I></B><B> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUBSCRIPTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Subscription Agreement (this &#147;<U>Agreement</U>&#148;) is dated as of December&nbsp;11, 2020 (the &#147;<U>Effective Date</U>&#148;),
among Lexicon Pharmaceuticals, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), Artal International S.C.A. (the &#147;Invus Purchasers&#148;) and each other purchaser identified on the signature pages hereto (each a
&#147;<U>Purchaser</U>&#148; and collectively with the Invus Purchasers, the &#147;<U>Purchasers</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, subject to the
terms and conditions set forth in this Agreement, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, the securities of the Company as more fully described in
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable
consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings set forth in this <U>Section</U><U></U><U>&nbsp;1.1</U>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Base Prospectus</U>&#148; means the prospectus related to the Common Stock, dated November&nbsp;18, 2019, which is a part of the
Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing</U>&#148; means the closing of the purchase and sale of the Securities pursuant to
<U>Section</U><U></U><U>&nbsp;2.1</U> of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Date</U>&#148; means the third Trading Day after the Effective
Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Commission</U>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Closing Price</U>&#148; means $3.20. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Stock</U>&#148; means the common stock of the Company, $0.001 par value per share, and any other class of securities into
which such securities may hereafter be reclassified or changed into. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of
1934, as amended, and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Investment Company Act</U>&#148; means the Investment
Company Act of 1940, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Placement Agent</U>&#148; means Citigroup Global Markets Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Prospectus Supplement</U>&#148; means the prospectus supplement complying with Rule 424(b) of the Securities Act that is delivered by
the Company to each Purchaser in connection with the execution and delivery of this Agreement, including all information incorporated by reference therein, and that is filed with the Commission pursuant to Rule 424(b) of the Securities Act. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registration Statement</U>&#148; means the effective registration statement on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> (Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;333-234568)</FONT> filed by the Company with the Commission pursuant to the Securities Act for the registration of the Common Stock, as such
Registration Statement may be amended and supplemented from time to time (including pursuant to Rule 462(b) of the Securities Act), including the Base Prospectus and all documents filed as part thereof or incorporated by reference therein, and
including all information deemed to be a part thereof at the time of effectiveness pursuant to Rule 430B of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities</U>&#148; means the shares of the Common Stock issued hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Act</U>&#148; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Short Sales</U>&#148; means all &#147;short sales&#148; as defined in Rule 200 of Regulation SHO of the Exchange Act, but shall be
deemed to not include the location and/or reservation of borrowable shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Day</U>&#148; means a day on
which the Common Stock is traded on a Trading Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Market</U>&#148; means The NASDAQ Global Select Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transaction Agreements</U>&#148; means, collectively, (i)&nbsp;the Stockholders&#146; Agreement, dated as of June&nbsp;17, 2007 (as
amended, supplemented or otherwise modified through the date hereof) and (ii)&nbsp;the Registration Rights Agreement, dated as of June&nbsp;17, 2007 (as amended, supplemented or otherwise modified through the date hereof). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transaction Documents</U>&#148; means this Agreement and any other documents or agreements executed and delivered to the Purchasers
in connection with the transactions contemplated hereunder. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURCHASE AND SALE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1
<U>Purchase and Sale at Closing</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">At the Closing, upon the terms and subject to the conditions set forth herein, the Company hereby
agrees to issue and sell to each Purchaser, and each Purchaser agrees to purchase from the Company, severally and not jointly, the number of shares of Common Stock set forth opposite such Purchaser&#146;s name on Exhibit A hereto, at a purchase
price equal to the Common Closing Price per share of Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Deliveries; Closing Conditions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">i. At the Closing, the Company will deliver or cause to be delivered to each Purchaser certificate(s) representing the Common Stock purchased
by such Purchaser, each registered in the Purchaser&#146;s name, or, if such Common Stock is held in book entry, proof acceptable to each Purchaser of the issuance of such Common Stock to such Issuer. Such delivery shall be against payment of the
purchase price therefor by the Purchaser by wire transfer or certified check of immediately available funds to the Company in accordance with the Company&#146;s written wiring instructions. The respective obligations of the Company, on the one hand,
and the Purchasers, on the other hand, hereunder in connection with the Closing are subject to the following conditions being met: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)
the accuracy in all material respects (except to the extent already qualified by materiality or Material Adverse Change, in which case, such representations and warranties shall be true and correct in all respects) on the Closing Date of the
representations and warranties contained herein (unless made as of a specified date therein) of the Company (with respect to the obligations of the Purchasers) and the Purchasers (with respect to the obligations of the Company); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the Purchasers shall have received on the Closing Date a certificate, dated the Closing Date and signed by an executive officer of the
Company, to the effect that the representations and warranties of the Company contained in this Agreement are true and correct as of the Closing Date (unless made as of a specified date therein) in all material respects (except to the extent already
qualified by materiality or Material Adverse Change, in which case, such representations and warranties shall be true and correct in all respects) and that the Company has complied in all material respects with all of the agreements and satisfied
all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date. The officer signing and delivering such certificate may rely upon the best of his or her knowledge as to proceedings threatened; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Substantially concurrently with the delivery of the Securities to the Purchasers, the Company and the Invus Purchasers shall enter into
Supplement No.&nbsp;3 to the Transaction Agreements in the form attached as Annex I hereto; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) At the Closing Date, the Company shall
have used its best efforts to list the Securities on the Trading Market; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) all other obligations, covenants and agreements of the
Company (with respect to the obligations of the Purchasers) and the Purchasers (with respect to the obligations of the Company) required to be performed at or prior to the Closing Date shall have been performed in all material respects. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Representations and Warranties of the Company</U>. The Company hereby makes the following representations and warranties set forth
below to each Purchaser as of the date hereof and as of the Closing: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">i. <U>Compliance with Registration Requirements</U>. The Registration
Statement has become effective under the Securities Act. The Company has complied, to the Commission&#146;s satisfaction with all requests of the Commission for additional or supplemental information, if any.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
No stop order suspending the effectiveness of the Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the best knowledge of the
Company, are contemplated or threatened by the Commission. At the time the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019 (the &#147;<U>Annual Report</U>&#148;) was filed
with the Commission, or, if later, at the time the Registration Statement was originally filed with the Commission, the Company met the then-applicable requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities
Act. The documents incorporated or deemed to be incorporated by reference in the Registration Statement, at the time they were or hereafter are filed with the Commission, or became effective under the Exchange Act, as the case may be, complied and
will comply in all material respects with the requirements of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">ii. <U>Disclosure</U>. The Prospectus Supplement and the
accompanying Base Prospectus when filed will comply in all material respects with the Securities Act. Each of the Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective, complied and will comply
in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. The
Prospectus Supplement (including any prospectus wrapper) and the accompanying Base Prospectus, as of its date, did not, and at the Closing Date, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances under which they were made, not misleading. There are no contracts or other documents required to be described in the Prospectus Supplement or to be filed as an exhibit to the
Registration Statement which have not been described or filed as required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">iii. <U>Subscription Agreement</U>. This Agreement has been
duly authorized, executed and delivered by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">iv. <U>Authorization of the Securities</U>. The Securities have been duly
authorized for issuance and sale pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and the issuance and sale of the
Securities is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Securities that have not been duly waived or satisfied. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">v. <U>No Applicable Registration or Other Similar Rights</U>. There are no persons with registration or other similar rights to have any equity
or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been duly waived. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">vi. <U>No Material Adverse Change</U>. Except as otherwise disclosed in the Registration Statement and the Prospectus Supplement, subsequent to
the respective dates as of which information is given in the Registration Statement and the Prospectus Supplement: (i)&nbsp;there has been no material adverse change, or any development that could be reasonably expected to result in a material
adverse change, in (A)&nbsp;the condition, financial or otherwise, or in the earnings, business, properties, operations, operating results, assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of
business, of the Company and its subsidiaries, considered as one entity or (B)&nbsp;the ability of the Company to consummate the transactions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contemplated by this Agreement or perform its obligations hereunder (any such change being referred to herein as a &#147;<B>Material Adverse Change</B>&#148;); (ii) the Company and its
subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with their business from fire, explosion, flood, earthquakes,
accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered
as one entity, and have not entered into any transactions not in the ordinary course of business; and (iii)&nbsp;there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of
the Company or its subsidiaries and there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Company&#146;s subsidiaries on any
class of capital stock, or any repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">vii.
<U>Independent Accountants</U>. Ernst&nbsp;&amp; Young LLP, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the
Registration Statement and the Prospectus Supplement, is (i)&nbsp;an independent registered public accounting firm as required by the Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board
(&#147;<B>PCAOB</B>&#148;), (ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule <FONT STYLE="white-space:nowrap">2-01</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the
Securities Act and (iii)&nbsp;a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">viii. <U>Financial Statements</U>. The financial statements filed with the Commission as a part of the Registration Statement and the
Prospectus Supplement present fairly in all material respects the consolidated financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations, changes in stockholders&#146; equity
and cash flows for the periods specified. Such financial statements have been prepared in conformity with generally accepted accounting principles applied on a consistent basis throughout the periods involved, except as may be expressly stated in
the related notes thereto. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared
in accordance with the Commission&#146;s rules and guidelines applicable thereto in all material respects. No other financial statements or supporting schedules are required to be included in the Registration Statement or the Prospectus Supplement.
The financial data set forth in each of the Registration Statement and the Prospectus Supplement under the caption &#147;Selected Financial Data&#148; fairly present in all material respects the information set forth therein on a basis consistent
with that of the audited financial statements contained in the Registration Statement and the Prospectus Supplement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">ix. <U>Company&#146;s
Accounting System</U>. The Company and each of its subsidiaries make and keep accurate books and records and maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in
accordance with management&#146;s general or specific authorization; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles as applied in the United
States and to maintain accountability for assets; (iii)&nbsp;access to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assets is permitted only in accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable
intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement and the Prospectus Supplement
fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">x. <U>Statistical and Market-Related Data</U>. All statistical, demographic and market-related data included in the Registration Statement or
the Prospectus Supplement are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all material respects or represent the Company&#146;s good faith estimates that are made on the basis
thereof. To the extent required, the Company has obtained the written consent for the use of such data from such sources. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xi.
<U>Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting</U>. Except as otherwise disclosed in the Prospectus Supplement, the Company has established and maintains disclosure controls and
procedures (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act), which (i)&nbsp;are designed to ensure that material information relating to the Company,
including its consolidated subsidiaries, is made known to the Company&#146;s principal executive officer and its principal financial officer by others within those entities, within the time periods specified in the Commission&#146;s rules and forms;
(ii)&nbsp;have been evaluated by management of the Company for effectiveness as of the end of the Company&#146;s most recent fiscal quarter; and (iii)&nbsp;are effective in all material respects to perform the functions for which they were
established. Since the end of the Company&#146;s most recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company&#146;s internal control over financial reporting (whether or not remediated) and no
change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. The Company is not aware of any change
in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xii. <U>Incorporation and Good Standing of the Company</U>. The Company has been duly incorporated and is validly existing as a corporation in
good standing under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement and the Prospectus
Supplement and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing in the State of Texas and each other jurisdiction in which the conduct
of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not result in a Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xiii. <U>Subsidiaries</U>. Each of the Company&#146;s &#147;subsidiaries&#148; (for purposes of this Agreement, as defined in Rule 405 under
the Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction of its
incorporation or organization and has the power and authority (corporate or other) to own, lease </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and operate its properties and to conduct its business as described in the Registration Statement and the Prospectus Supplement. Each of the Company&#146;s subsidiaries is duly qualified as a
foreign corporation, partnership or limited liability company, as applicable, to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification,
except to the extent that the failure to be so qualified or be in good standing would not result in a Material Adverse Change. All of the issued and outstanding capital stock or other equity or ownership interests of each of the Company&#146;s
subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and, except as otherwise disclosed in the Prospectus Supplement, are owned by the Company, directly or through subsidiaries, free and clear of any security
interest, mortgage, pledge, lien, encumbrance or adverse claim. The Company does not own or control, directly or indirectly, any corporation, association or other entity that would constitute a significant subsidiary as defined under Rule <FONT
STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> other than the subsidiaries listed in Exhibit 21 to the Annual Report. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xiv. <U>Capitalization and Other Capital Stock Matters</U>. The issued and outstanding capital stock of the Company is as set forth in the
Registration Statement and the Prospectus Supplement under the caption &#147;The Offering&#148; (other than for subsequent issuances, if any, pursuant to employee benefit plans or upon the exercise of outstanding options or warrants, or upon
conversion of convertible notes in each case described in the Registration Statement and the Prospectus Supplement). The Common Stock (including the Shares) conform in all material respects to the description thereof contained in the Prospectus
Supplement. All of the issued and outstanding Common Stock have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all federal and state securities laws. None of the outstanding Common
Stock was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of
first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than those described in the Registration Statement and the
Prospectus Supplement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xv. <U>Stock Exchange Listing</U>. The Common Stock is registered pursuant to Section&nbsp;12(b) or 12(g) of the
Exchange Act and are listed on the Trading Market, and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock
from the Trading Market, nor has the Company received any notification that the Commission or the Trading Market is contemplating terminating such registration or listing. To the Company&#146;s knowledge, it is in compliance in all material respects
with all applicable listing requirements of the Trading Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xvi. <U><FONT STYLE="white-space:nowrap">Non-Contravention</FONT> of
Existing Instruments; No Further Authorizations or Approvals Required</U>. Neither the Company nor any of its subsidiaries is in violation of its charter or bylaws, partnership agreement or operating agreement or similar organizational documents, as
applicable, or is in default (or, with the giving of notice or lapse of time, would be in default) (&#147;<B>Default</B>&#148;) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument
(including, without limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by
which it </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or any of them may be bound, or to which any of their respective properties or assets are subject, except for such Defaults as could not be expected, individually or in the aggregate, to result
in a Material Adverse Change. The Company&#146;s execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby and the issuance and sale of the Securities will not contravene (i)&nbsp;the provisions of
the charter or by laws, partnership agreement or operating agreement or similar organizational documents, as applicable, of the Company or any subsidiary, (ii)&nbsp;any agreement or other instrument binding upon the Company or any of its
subsidiaries that is material to the Company and its subsidiaries, taken as a whole, and (iii)&nbsp;any law, administrative regulation or administrative or court decree applicable to the Company or any of its subsidiaries; except, in the case of
clauses (ii)&nbsp;and (iii), as would not reasonably be expected to result in a Material Adverse Change. No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority
or agency, is required for the Company&#146;s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby, except such as (i)&nbsp;have been obtained or made by the Company and are in full force and
effect under the Securities Act, (ii)&nbsp;as may be required under applicable state securities or blue sky laws or FINRA and (iii)&nbsp;if not obtained, have not or would not reasonably be expected to result in a Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xvii. <U>No Material Actions or Proceedings</U>. Except as otherwise disclosed in the Prospectus Supplement, there is no action, suit,
proceeding, inquiry or investigation brought by or before any legal or governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which could be expected,
individually or in the aggregate, to result in a Material Adverse Change. No material labor dispute with the employees of the Company exists, except as described in the Prospectus Supplement, or, to the knowledge of the Company, is imminent; and the
Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that could result in a Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xviii. <U>Intellectual Property Rights</U>. Except as otherwise disclosed in the Registration Statement or the Prospectus Supplement, the
Company and its subsidiaries own, or have rights to use the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the Registration Statement and the
Prospectus Supplement as being owned or licensed by them or which are used in and necessary for the conduct of their respective businesses as currently conducted or as currently proposed to be conducted (collectively, &#147;<B>Intellectual
Property</B>&#148;) and, to the Company&#146;s knowledge, the conduct of their respective businesses does not and will not infringe or misappropriate in any material respect any such rights of others. The Intellectual Property owned by the Company
has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part, and the Company is unaware of any facts which would form a reasonable basis for any such adjudication. To the Company&#146;s knowledge:
(i)&nbsp;except as otherwise disclosed in the Prospectus Supplement and with respect to LX9211 (to which the Company owns an exclusive license), there are no third parties who have ownership, royalty, or exclusive license rights to any Intellectual
Property owned by the Company, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement and the Prospectus Supplement as licensed to the Company or one or
more of its subsidiaries; and (ii)&nbsp;there is no material infringement by third parties of any Intellectual Property owned by the Company. There is no pending or, to the Company&#146;s knowledge, threatened
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
action, suit, proceeding or claim by others: (A)&nbsp;challenging the Company&#146;s rights in or to any Intellectual Property licensed to the Company; (B)&nbsp;challenging the validity,
enforceability or scope of any Intellectual Property owned by the Company; or (C)&nbsp;asserting that the Company or any of its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described in
the Registration Statement or the Prospectus Supplement as under development, infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret or other intellectual rights of others. The Company and its subsidiaries have
materially complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any subsidiary, and all such agreements are, to the Company&#146;s knowledge, in full force and effect. To the
Company&#146;s knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual Property. The Company and its subsidiaries have taken reasonable steps to protect, maintain and safeguard Intellectual
Property owned by the Company, including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their employees, and, to the Company&#146;s knowledge, no employee of
the Company is in or has been in violation of any term of any such agreement. The duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of the United States patents and patent applications
included in the Intellectual Property owned by the Company have been materially complied with; and in all foreign offices having similar requirements, all such requirements have been materially complied with. The product candidates described in the
Registration Statement and the Prospectus Supplement as under development by the Company or any subsidiary fall within the scope of the claims of one or more patents owned by, or exclusively licensed to, the Company or any subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xix. <U>All Necessary Permits, etc</U>. Except as otherwise disclosed in the Prospectus Supplement, the Company and each subsidiary possess
such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and as described in the Registration Statement or the
Prospectus Supplement (&#147;<B>Permits</B>&#148;), except as would not reasonably be expected to result in a Material Adverse Change, and the Company has not received any notice of proceedings relating to the revocation or modification of any such
certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xx. <U>Title to Properties</U>. Except as otherwise disclosed in the Prospectus Supplement, the Company and its subsidiaries have good and
marketable title to all of the real and personal property and other assets owned by them which is material to the business of the Company, in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse
claims and other defects except as do not materially affect the value of such property and do not interfere in any material respect with the use made and currently proposed to be made of such property by the Company. Except as otherwise disclosed in
the Prospectus Supplement, the real property, improvements, equipment and personal property held under lease by the Company or any of its subsidiaries are held under valid and enforceable leases, with such exceptions as are not material and do not
materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company or such subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xxi. <U>Tax Law Compliance</U>. Except as would not, individually or in the aggregate,
reasonably be expected to result in a Material Adverse Change, the Company and its subsidiaries (i)&nbsp;have filed all necessary federal, state and foreign income and franchise tax returns or have properly requested extensions thereof and
(ii)&nbsp;have paid all taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine or penalty levied against any of them, except as may be being contested in good faith and by appropriate proceedings
and for which adequate reserves are maintained in accordance with generally accepted accounting principles. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xxii. <U>Company Not an
&#147;Investment Company</U>.&#148; The Company is not, and will not be, either after receipt of payment for the Securities or after the application of the proceeds therefrom as described under &#147;Use of Proceeds&#148; in the Registration
Statement or the Prospectus Supplement, required to register as an &#147;investment company&#148; under the Investment Company Act . </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xxiii. <U>Insurance</U>. The Company is insured by insurers of recognized financial responsibility against such losses and risks and in such
amounts as are prudent and customary in the businesses in which it is engaged. The Company has no reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or obtain similar coverage from
similar insurers as may be necessary to continue its business at a cost that would not result in a Material Adverse Change, except as described in the Prospectus Supplement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xxiv. <U>No Price Stabilization or Manipulation; Compliance with Regulation M</U>. Neither the Company nor any of its subsidiaries has taken,
directly or indirectly, any action designed to or that reasonably would be expected to cause or result in stabilization or manipulation of the price of the Common Stock or of any &#147;reference security&#148; (as defined in Rule 100 of Regulation M
under the Exchange Act (&#147;<B>Regulation M</B>&#148;)) with respect to the Common Stock, whether to facilitate the sale or resale of the Securities or otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xxv. <U>Related Party Transactions</U>. There are no business relationships or related-party transactions involving the Company or any of its
subsidiaries or any other person required to be described in the Registration Statement or the Prospectus Supplement which have not been described as required. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xxvi. <U>No Unlawful Contributions or Other Payments</U>. Except as otherwise disclosed in the Prospectus Supplement, neither the Company nor
any of its subsidiaries nor, to the best of the Company&#146;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office
in violation of any law or of the character required to be disclosed in the Registration Statement and the Prospectus Supplement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xxvii.
<U>Compliance with Environmental Laws</U>. Except as described in the Prospectus Supplement and except as could not be expected, individually or in the aggregate, to result in a Material Adverse Change, (i)&nbsp;neither the Company nor any of its
subsidiaries is in violation of any applicable federal, state, local or foreign statute, law (including fundamental principles of common law), rule, regulation or ordinance, including any judicial or administrative interpretation thereof, relating
to pollution or protection of human health (to the extent relating to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exposure to Hazardous Materials, defined below), the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife,
including, without limitation, laws and regulations relating to the release of pollutants, contaminants, or hazardous or toxic wastes or substances that are subject to regulation by any governmental authority (collectively, &#147;<B>Hazardous
Materials</B>&#148;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#147;<B>Environmental Laws</B>&#148;), (ii) the Company and its subsidiaries have
all permits, authorizations and approvals required of them under Environmental Laws for their operations has currently conducted and are each in compliance with the terms and conditions of such permits, authorizations and approvals, and
(iii)&nbsp;the Company and its subsidiaries has not received written notice of any pending or threatened liability under any Environmental Law and, to the knowledge of the Company, there is no event or occurrence that would reasonably be expected to
result in the receipt of any such notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xxviii. <U>ERISA Compliance</U>. Except as would not, individually or in the aggregate, result
in a Material Adverse Change: (i)&nbsp;the Company and its subsidiaries and any &#147;employee benefit plan&#148; (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations
thereunder (collectively, &#147;<B>ERISA</B>&#148;)) established or maintained by the Company, its subsidiaries or their &#147;ERISA Affiliates&#148; (as defined below) are in compliance in all material respects with ERISA; &#147;<B>ERISA
Affiliate</B>&#148; means, with respect to the Company or any of its subsidiaries, any member of any group of organizations described in Sections 414(b), (c), (m) or (o)&nbsp;of the Internal Revenue Code of 1986, as amended, and the regulations and
published interpretations thereunder (the &#147;<B>Code</B>&#148;) of which the Company or such subsidiary is a member; (ii)&nbsp;no &#147;reportable event&#148; (as defined under ERISA), other than an event for which the <FONT
STYLE="white-space:nowrap">30-day</FONT> notice period is waived, has occurred or is reasonably expected to occur with respect to any &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA
Affiliates; (iii)&nbsp;no &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such &#147;employee benefit plan&#148; were terminated, would have any &#147;amount of
unfunded benefit liabilities&#148; (as defined under ERISA); (iv) neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (a)&nbsp;Title IV of ERISA with respect to
termination of, or withdrawal from, any &#147;employee benefit plan&#148; or (b)&nbsp;Sections 412, 4971, 4975 or 4980B of the Code; and (v)&nbsp;each &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or
any of their ERISA Affiliates that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act, which would reasonably be expected to cause the loss of such
qualification. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xxix. <U>Brokers</U>. Except as otherwise disclosed in the Prospectus Supplement, there is no broker, finder or other party
that is entitled to receive from the Company any brokerage or finder&#146;s fee or other fee or commission as a result of any transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xxx. <U>Compliance with Laws</U>. Except as otherwise disclosed in the Prospectus Supplement, the Company and its subsidiaries are in
compliance with all applicable laws, rules and regulations, except where failure to be so in compliance could not be expected, individually or in the aggregate, to result in a Material Adverse Change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xxxi. <U>Anti-Corruption and Anti-Bribery Laws</U>. Neither the Company nor any of its
subsidiaries nor, to the knowledge of the Company, any director, officer, or employee of the Company or any of its subsidiaries, nor to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its
subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political
activity; (ii)&nbsp;made or taken any act in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or
controlled entity or public international organization, or any political party, party official, or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended
(the &#147;<B>FCPA</B>&#148;), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, authorized, requested, or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence
payment, kickback or other unlawful payment or benefit. The Company and its subsidiaries and, to the knowledge of the Company, the Company&#146;s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted
and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xxxii. <U>Money Laundering Laws</U>. The operations of the Company and its subsidiaries are, and have been conducted at all times, in
compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations
thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<B>Money Laundering Laws</B>&#148;) and no action, suit or proceeding by or
before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xxxiii. <U>Clinical Data and Regulatory Compliance</U>. The preclinical tests and clinical trials, and other studies (collectively,
&#147;studies&#148;) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus Supplement were and, if still pending, are, to the Company&#146;s knowledge, being conducted in all material
respects in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company; the
descriptions of the results of such studies do not contain any misstatement of a material fact or omit to state a material fact necessary to make such statements not misleading, and the Company and its subsidiaries have no knowledge of any other
studies the results of which reasonably call into question the results described or referred to in the Registration Statement or the Prospectus Supplement; the Company and its subsidiaries have made all such filings and obtained all such approvals
as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility
Institutional Review Board (collectively, the &#147;<B>Regulatory Agencies</B>&#148;) except where failure to do so would not result in a Material Adverse Change; neither the Company nor any of its subsidiaries has received any notice of, or
correspondence from, any Regulatory Agency requiring the termination, suspension or material modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus Supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xxxiv. <U>Sanctions</U>. Neither the Company nor any of its subsidiaries, nor, to the
knowledge of the Company, directors, officers, or employees, nor, to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any U.S.
sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#147;<B>OFAC</B>&#148;) or the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury of
the United Kingdom, or other relevant sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;); nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target of
Sanctions, including, without limitation, Crimea, Cuba, Iran, North Korea, and Syria; and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary,
or any joint venture partner or other person or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that at the time of such financing, is the subject or the target of Sanctions or in
any other manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the past five years, the Company and its
subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned
Country. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xxxv. <U>Sarbanes-Oxley</U>. The Company is in compliance, in all material respects, with all applicable provisions of the
Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xxxvi. <U>Cybersecurity</U>. The Company&#146;s and its
subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, and databases (collectively, &#147;<B>IT Systems</B>&#148;) are reasonably adequate for the operation of the business of the Company and its
subsidiaries as currently conducted. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their
material confidential information and the integrity, operation, redundancy and security of all IT Systems and data, including &#147;Personal Data,&#148; used in connection with their businesses. &#147;<B>Personal Data</B>&#148; means (i)&nbsp;a
natural person&#146;s name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number, passport number, credit card number,
or bank account information; (ii)&nbsp;any information which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; (iii) &#147;personal data&#148; as defined by GDPR (as defined below);
(iv) any information which would qualify as &#147;protected health information&#148; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act
(collectively, &#147;<B>HIPAA</B>&#148;); and (v)&nbsp;any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified
person&#146;s health or sexual orientation. In the past three (3)&nbsp;years, there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability
or the duty to notify any other person under Privacy Laws (as defined below). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xxxvii. <U>Compliance with Data Privacy Laws</U>. The Company and its subsidiaries are, and
at all prior times were, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its subsidiaries have taken commercially reasonable actions
to prepare to comply with, and since May&nbsp;25, 2018, have been and currently are in material compliance with, the European Union General Data Protection Regulation (&#147;<B>GDPR</B>&#148;) (EU 2016/679) (collectively, the &#147;<B>Privacy
Laws</B>&#148;). To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with the Company&#146;s policies
and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the &#147;<B>Policies</B>&#148;). The Company further certifies that neither it nor any subsidiary:
(i)&nbsp;has received written notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation,
remediation, or other corrective action initiated by a governmental authority pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or settlement agreement issued by a governmental authority that imposes any obligation or
liability under any Privacy Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">xxxviii. <U>Compliance with Health Care Laws</U>. The Company and its subsidiaries are, and at all times
have been, in compliance with all applicable Health Care Laws, except to the extent that any <FONT STYLE="white-space:nowrap">non-compliance</FONT> would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse
Change. For purposes of this Agreement, &#147;<B>Health Care Laws</B>&#148; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301 et seq.), the Public Health Service Act (42 U.S.C. Section&nbsp;201 et seq.), and the
regulations promulgated thereunder; (ii)&nbsp;all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal false statements law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> 18
U.S.C. Sections 286 and 287, the health care fraud criminal provisions under HIPAA (42 U.S.C. Section&nbsp;1320d et seq.), the Stark Law (42 U.S.C. Section&nbsp;1395nn), the civil monetary penalties law (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7a),</FONT> the exclusion law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the Physician Payments Sunshine Act (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320-7h),</FONT> and applicable laws governing government funded or sponsored healthcare programs; (iii)&nbsp;HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act
(42 U.S.C. Section&nbsp;17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation requirements under
applicable federal, state, local or foreign laws or regulatory bodies; and (vi)&nbsp;all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company or its subsidiaries, and (vii)&nbsp;the
directives and regulations promulgated pursuant to such statutes and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof. Neither the Company nor any of its subsidiaries has received written notice of any claim, action,
suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care
Laws nor, to the Company&#146;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened, except in each case as would not, individually or in the aggregate, reasonably be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expected to result in a Material Adverse Change. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records,
claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date
filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement
orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its subsidiaries nor, to the knowledge of the Company, any of their respective employees, officers, directors, or
agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other
similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Representations, Warranties and
Covenants of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents, warrants and covenants as of the date hereof and as of the Closing: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">i. <U>Authorization</U>. Purchaser represents and warrants to the Company that: (a)&nbsp;Purchaser has all requisite legal and corporate or
other power and capacity and has taken all requisite corporate or other action to execute and deliver this Agreement, to purchase the Securities and to carry out and perform all of its obligations under this Agreement; and (b)&nbsp;this Agreement
constitutes the legal, valid and binding obligation of the Purchaser, enforceable against the Purchaser in accordance with its terms, except (i)&nbsp;as limited by applicable bankruptcy, insolvency, reorganization or similar laws relating to or
affecting the enforcement of creditors&#146; rights generally and (ii)&nbsp;as limited by equitable principles generally. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">ii.
<U>Investment Experience; Access to Information</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is: (i)&nbsp;an &#147;accredited investor&#148; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or
(a)(8) under the Securities Act or (ii)&nbsp;a &#147;qualified institutional buyer&#148; as defined in Rule 144A(a) under the Securities Act. Purchaser is aware of the Company&#146;s business affairs and financial condition and has had access to and
has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Securities. Purchaser has such business and financial experience as is required to give it the capacity to protect its own interests
in connection with the purchase of the Securities. Purchaser acknowledges that it has had the opportunity to review the Company&#146;s filings with the Commission and has been afforded (i)&nbsp;the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii)&nbsp;access to information about the
Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii)&nbsp;the opportunity to obtain such additional information that the Company
possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. Purchaser has sought such accounting, legal and tax advice as it has considered necessary to
make an informed decision with respect to its acquisition of the Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">iii. Each Purchaser has not directly or indirectly, nor has any person acting on behalf of
or pursuant to any understanding with the Purchaser, engaged in any purchases or sales of the Company&#146;s securities (including, without limitation, any Short Sales involving the Company&#146;s securities) since the time that the Purchaser was
first contacted by the Company or any other person regarding the transactions contemplated hereby. Each Purchaser covenants that neither it nor any person acting on its behalf or pursuant to any understanding with it will engage in any purchases or
sales of the Company&#146;s securities (including, without limitation, any Short Sales involving the Company&#146;s securities) prior to the time that the transactions contemplated by this Agreement are publicly disclosed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">iv. <U>No Legal, Tax or Investment Advice</U>. Purchaser has independently evaluated the merits of its decision to purchase Securities pursuant
to this Agreement. Purchaser understands that nothing in this Agreement or any other materials presented to Purchaser in connection with the purchase and sale of the Securities constitutes legal, tax or investment advice. Purchaser has consulted
such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">v. <U>Confidentiality</U>. Purchaser will hold in confidence all information concerning this Agreement and the sale and issuance of the
Securities until the Company has made a public announcement concerning this Agreement and the sale and issuance of the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">vi.
<U>Governmental Review</U>. Purchaser understands that no United States federal or state agency or any other government or governmental agency has passed upon or made any recommendation or endorsement of the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">vii. <U>Beneficial Ownership</U>. Immediately prior to the Closing, Purchaser, together with its affiliates and any other persons acting as a
group together with the Purchaser and any of its affiliates, beneficially owned the number of shares of Common Stock set forth on such Purchaser&#146;s signature page attached hereto (as such ownership is calculated pursuant to the rules of Nasdaq).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">viii. <U>Foreign Investors</U>. If Purchaser is not a United States person (as defined by Section&nbsp;7701(a)(30) of the Code), Purchaser
hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Securities or any use of this Agreement, including (a)&nbsp;the legal requirements within
its jurisdiction for the purchase of the Securities, (b)&nbsp;any foreign exchange restrictions applicable to such purchase or acquisition, (c)&nbsp;any government or other consents that may need to be obtained, and (d)&nbsp;the income tax and other
tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or transfer of the Securities. The Purchaser&#146;s subscription and payment for and continued beneficial ownership of the Securities will not violate any
applicable securities or other laws of the Purchaser&#146;s jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER AGREEMENTS OF THE PARTIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Integration</U>. Except as contemplated by the terms of this Agreement, the Company shall not sell, offer for sale or solicit offers to
buy or otherwise negotiate in respect of any security (as defined in Section&nbsp;2 of the Securities Act) that would be integrated with the offer or sale of the Securities such that the rules of the Trading Market would require shareholder approval
of this transaction prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Securities Laws Disclosure; Publicity</U>. The Company shall: (a)&nbsp;issue a press release disclosing the material terms of the
transactions contemplated hereby promptly following the execution and delivery hereof (the &#147;<U>Press Release</U>&#148;), and (b)&nbsp;by 5:30 p.m. (New York City time) on the fourth Trading Day following the Effective Date, file a Current
Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> disclosing the material terms of the transactions contemplated hereby (the &#147;<U>Form <FONT STYLE="white-space:nowrap">8-K</FONT></U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Use of Proceeds</U>. The Company will use the proceeds from the offering as described in the Prospectus Supplement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <U>Amendment to the Certification of Incorporation</U>. The Company shall take all necessary actions to (i)&nbsp;include the Charter
Amendment (as defined below) as a matter to be considered and acted upon by its stockholders in the applicable proxy statement to be sent to stockholders in advance of the Company&#146;s next annual meeting of stockholders, which proxy statement
shall include the Board of Director&#146;s recommendation that the stockholders of the Company vote in favor of such amendment, and (ii)&nbsp;solicit from stockholders eligible to vote at such meeting proxies in favor of the Charter
Amendment.&nbsp;In the event that the Charter Amendment is not approved by the requisite number of stockholders eligible to vote at such meeting, the Company shall, in advance of subsequent annual or special meetings of its stockholders, take all
necessary actions to (i)&nbsp;include the Charter Amendment as a matter to be considered and acted upon by its stockholders in the applicable proxy statement to be sent to stockholders in connection with such meeting, which proxy statement shall
include the Board of Director&#146;s recommendation that the stockholders of the Company vote in favor of such amendment, and (ii)&nbsp;solicit from stockholders eligible to vote at such meetings proxies in favor of the Charter Amendment, until the
Charter Amendment is approved by the requisite number of stockholders. For purposes of this Agreement, &#147;Charter Amendment&#148; shall mean an Amendment to the Company&#146;s Certificate of Incorporation that grants holders of 20% or more of the
Company&#146;s issued and outstanding Common Stock (i)&nbsp;customary <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights and (ii)&nbsp;consent rights prior to the Company taking any of the following actions (x)&nbsp;creating or issuing any
new class or series of shares of capital stock of the Company (or securities convertible into or exercisable for shares of capital stock of the Company) having rights, preferences or privileges senior to or on parity with the Common Stock,
(y)&nbsp;subject to certain customary exceptions, repurchasing, retiring, redeeming or otherwise acquiring any equity securities (or securities convertible into or exchangeable for equity securities) of the Company or any subsidiary of the Company
and (z)&nbsp;adopting, or proposing to adopt, or maintaining any shareholders&#146; rights plan, &#147;poison pill&#148; or other similar plan or agreement, unless such stockholder is exempt from the provisions of such shareholders&#146; rights
plan, &#147;poison pill&#148; or other similar plan or agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;5 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1
<U>Termination</U>. This Agreement may be terminated by any Purchaser, as to such Purchaser&#146;s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the
other parties, if the Closing has not been consummated within ten calendar days from the Effective Date through no fault of such Purchaser; <I>provided</I>, <I>however</I>, that no such termination will affect the right of any party to sue for any
breach by the other party (or parties). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the
contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this
Agreement. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of
the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such subject matter, which the parties acknowledge have been merged into such documents, exhibits and
schedules. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder
shall be in writing and shall be deemed given and effective upon actual receipt via mail, courier or confirmed email by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on
the signature pages attached hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Amendments; Waivers</U>. No provision of this Agreement may be waived or amended except in a
written instrument signed, in the case of an amendment, by (a)&nbsp;the Company and (b)&nbsp;Purchasers holding at least a majority of the Securities or, in the case of a waiver, by the party against whom enforcement of any such waived provision is
sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or
requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit
or affect any of the provisions hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 <U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit
of the parties and their permitted successors and assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). The Purchasers may not assign
this Agreement or any rights or obligations hereunder without the prior written consent of the Company (other than by merger). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8 <U>No Third-Party Beneficiaries</U>. The Placement Agents shall be the third party
beneficiary of the representations and warranties of the Company in <U>Section</U><U></U><U>&nbsp;3.1</U> and the representations, warranties and covenants of the Purchasers in <U>Section</U><U></U><U>&nbsp;3.2</U>. This Agreement is intended for
the benefit of the parties hereto and their respective permitted successors and assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person, except as otherwise set forth in this
<U>Section</U><U></U><U>&nbsp;5.8</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.9 <U>Governing Law</U>. All questions concerning the construction, validity, enforcement and
interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflicts of law thereof. Each party agrees that all legal
proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers,
shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the State of Delaware. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the
State of Delaware for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby
irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such
proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence
of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in
any way any right to serve process in any other manner permitted by law. If either party shall commence an action or proceeding to enforce any provisions of the Transaction Documents, then the prevailing party in such action or proceeding shall be
reimbursed by the other party for its reasonable attorneys&#146; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.10 <U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and
the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature on this
Agreement is delivered by facsimile transmission or by <FONT STYLE="white-space:nowrap">e-mail</FONT> delivery of a &#147;.pdf&#148; format data file, such signature shall create a legally valid and binding obligation of the party executing (or on
whose behalf such signature is executed) with the same force and effect as if such facsimile or &#147;.pdf&#148; signature page were an original thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.11 <U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be
invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall
use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be
the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.12 <U>Replacement of Securities</U>. If any certificate or instrument evidencing any
Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate
or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity or bond, if requested. The applicant for a new certificate or instrument under such
circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.13 <U>Remedies</U>. The Company and the Purchasers shall be entitled to exercise all rights provided herein or granted by law, including
recovery of damages, for any breach of the Transaction Documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.14 <U>Independent Nature of Purchasers&#146; Obligations and
Rights</U>. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or <FONT
STYLE="white-space:nowrap">non-performance</FONT> of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant thereto, shall
be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the
transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights, including without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.15 <U>Construction</U>. The parties agree that each of them and/or their respective counsel has reviewed and had an opportunity to revise the
Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments hereto.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.16 <U>WAIVER OF JURY TRIAL</U>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.17 <U>Indemnification</U>. The Company hereby agrees to indemnify and hold harmless each of the Purchasers and each of their respective
affiliates, directors, officers, agents and employees and each person, if any, who controls such Purchasers within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act (collectively, the
&#147;<U>Indemnitees</U>&#148;) from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or other expenses reasonably incurred in connection with defending or investigating any such action or claim) arising out of or relating to any of the transactions contemplated by this Agreement.
For the avoidance of doubt and notwithstanding the foregoing, the Company shall not be deemed to indemnify and hold harmless the Indemnitees from and against any losses resulting from a decrease in the trading price of their Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Subscription Agreement to be duly
executed by their respective authorized signatories as of the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LEXICON PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey L. Wade </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Jeffrey L. Wade</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: Chief Financial Officer&nbsp;&amp; EVP Corp&nbsp;&amp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Admin Affairs</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>Address for Notice</U>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Lexicon Pharmaceuticals, Inc. 8800 Technology Forest Place</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">The Woodlands, Texas 77381</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attention: Brian T. Crum</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Facsimile: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">281-863-8010</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">with a copy (which shall not constitute notice) to:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Vinson&nbsp;&amp; Elkins LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">1001 Fannin Street, Suite 2500</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Houston, Texas 77002</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attention: David Oelman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Facsimile: (713) <FONT STYLE="white-space:nowrap">615-5861</FONT></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Subscription Agreement </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Biotechnology Value Fund, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Executive Officer BVF I GP LLC, itself General Partner of Biotechnology Value Fund, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Biotechnology Value Fund II, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Executive Officer BVF II GP LLC, itself General Partner of Biotechnology Value Fund II, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Biotechnology Value Trading Fund OS, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: President BVF Inc., General Partner of BVF Partners L.P., itself sole member of BVF Partners OS Ltd., itself GP of Biotechnology Value Trading Fund OS, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MSI BVF SPV, L.L.C.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: President BVF Inc., General Partner of BVF Partners L.P., itself <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for MSI BVF SPV, L.L.C.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>Address for Notice for BVF Entities</U>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BVF Partners L.P.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">44 Montgomery Street, 40th Floor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Subscription Agreement </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARTAL INTERNATIONAL S.C.A.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: ARTAL INTERNATIONAL MANAGEMENT S.A., its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Anne Goffard</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Anne Goffard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Address for Notice</U>:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Artal International, S.C.A.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">44, rue de la Val&eacute;e</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">L-2661 Luxembourg</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Page to </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Subscription Agreement </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CLOSING SCHEDULE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Common&nbsp;Stock&nbsp;to<BR>be Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Purchase&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology Value Fund, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,984,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,951,968.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology Value Fund II, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,608,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,548,281.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology Value Trading Fund OS, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">605,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,936,985.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MSI BVF SPV, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">562,764.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Artal International S.C.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,937,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20,312,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>65,000,000.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX I </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>d68225dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>20,312,500 SHARES OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLACEMENT AGENCY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">December&nbsp;11, 2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets
Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">388 Greenwich St. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10013 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lexicon Pharmaceuticals,
Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes, subject to the terms and conditions of this Placement Agency Agreement (the &#147;<B>Agreement</B>&#148;) and the Purchase Agreements (as defined in Section&nbsp;1(a) hereof),
to sell to certain investors (each, an &#147;<B>Investor</B>&#148; and collectively, the &#147;<B>Investors</B>&#148;) an aggregate of 20,312,500 shares (the &#147;<B>Shares</B>&#148;) of the Company&#146;s common stock, par value $0.001 (the
&#147;<B>Common Stock</B>&#148;), in an offering under the Company&#146;s registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-234568).</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Agreement to Act as Placement Agents</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with you as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) On the basis of the representations, warranties and agreements of the Company contained herein, and subject to all the terms and conditions
of this Agreement, Citigroup Global Markets Inc. (&#147;<B>Citigroup</B>&#148;) shall be the Company&#146;s exclusive placement agent (the &#147;<B>Placement Agent</B>&#148;, and if Citigroup is the only Placement Agent, all references to
&#147;<B>Placement Agents</B>&#148; in this Agreement shall refer only to Citigroup), acting on a reasonable best efforts basis, in connection with the sale by the Company of the Shares to the Investors in a proposed offering pursuant to the
Registration Statement, with the terms of the offering to be subject to market conditions and negotiations among the Company and the prospective Investors (such offering shall be referred to herein as the &#147;<B>Offering</B>&#148;). As
compensation for services rendered, and provided that any of the Shares are sold to Investors in the Offering, on the Closing Date (as defined in Section&nbsp;1(c) hereof) of the Offering, the Company shall pay to the Placement Agents a cash fee
equal to six percent (6%) of the aggregate gross proceeds raised in the Offering at the Closing, provided, that no fee shall be paid on the gross proceeds received from any Shares sold to Invus, L.P. or its affiliates (the &#147;<B>Placement
Fee</B>&#148;). The sale of the Shares shall be made pursuant to subscription agreements in the form included as Exhibit A hereto (each, a &#147;<B>Purchase Agreement</B>&#148; and collectively, the &#147;<B>Purchase Agreements</B>&#148;) on the
terms described on Exhibit B hereto. Each Placement Agent shall communicate to the Company, orally or in writing, each offer to purchase Shares received by such Placement Agent. The Company shall have the sole right to accept offers to purchase the
Shares and may reject any such offer in whole or in part. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) This Agreement shall not give rise to any commitment by the Placement Agents
to purchase any of the Shares, and the Placement Agents shall have no authority to bind the Company to accept offers to purchase the Shares. Each Placement Agent represents and agrees that, without the prior written consent of the Company, it has
not made and will not make any offer relating to the Shares that would constitute a Free Writing Prospectus that would be required to be filed with the Commission. Each Placement Agent may, with the prior consent of the Company (such consent not to
be unreasonably withheld), retain other brokers or dealers to act as <FONT STYLE="white-space:nowrap">sub-agents</FONT> on its behalf in connection with the Offering, the fees of which shall be paid out of such Placement Agent&#146;s portion of the
Placement Fee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Payment of the purchase price for, and delivery of, the Shares shall be made at a
closing (the &#147;<B>Closing</B>&#148;) by email exchange of documentation at 10:00 a.m., New York City time, on or before December&nbsp;16, 2020, or at such time on such other date as may be agreed upon in writing by the Placement Agents and the
Company (such date of payment and delivery being herein called the &#147;<B>Closing Date</B>&#148;). All such actions taken at the Closing shall be deemed to have occurred simultaneously. No Shares which the Company has agreed to sell pursuant to
the Purchase Agreements shall be deemed to have been purchased and paid for, or sold by the Company, until such Shares shall have been delivered to the Investor thereof against payment therefor by such Investor. If the Company shall default in its
obligations to deliver the Shares to an Investor whose offer it has accepted, the Company shall indemnify and hold the Placement Agents harmless against any loss, claim or damage incurred by the Placement Agents arising from or as a result of such
default by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) On the Closing Date, (i)&nbsp;the Company shall deliver, or cause to be delivered, the Shares to the Investors
or their designees, and the Investors shall deliver, or cause to be delivered, the purchase price for their respective Shares to the Company pursuant to the terms of the Purchase Agreements, &#147;delivery versus payment&#148; through the facilities
of The Depository Trust Company (&#147;<B>DTC</B>&#148;) and (ii)&nbsp;the Company shall wire the amounts owed to the Placement Agents as provided in this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Shares shall be registered in such names and in such denominations as each Investor shall request by written notice to the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Company acknowledges and agrees that the Placement Agents are acting solely in the capacity of an arm&#146;s length contractual
counterparty to the Company with respect to the Offering contemplated hereby (including in connection with determining the terms of the Offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person.
Additionally, the Placement Agents are not advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters and
shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and the Placement Agents shall have no responsibility or liability to the Company with respect thereto. Any review by the
Placement Agents of the Company, the transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Placement Agents and shall not be on behalf of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Representations, Warranties and Agreements of the Company</U>. The Company represents and warrants to, and agrees with, the Placement
Agents as of the date hereof, and as of the Closing Date, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company meets the requirements for use of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively, the &#147;<B>Act</B>&#148;) and has prepared and filed with the Commission a shelf registration statement, as
defined in Rule 405 (file number <FONT STYLE="white-space:nowrap">333-234568)</FONT> on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> including a related Base Prospectus, for registration under the Act of the offering and sale of the Shares. The
Company may have filed one or more amendments thereto, including any Preliminary Prospectus Supplement, each of which has previously been furnished to you and has become effective upon filing. The Company will next file with the Commission a Final
Prospectus Supplement relating to the Shares in accordance with Rule 424(b). The Registration Statement, at the Execution Time, is effective and meets the requirements set forth in Rule 415(a)(1)(x). There is no order preventing or suspending the
use of the Registration Statement, the Pricing Disclosure Package or the Final Prospectus Supplement, and, to the knowledge of the Company, no proceeding for that purpose or pursuant to Section&nbsp;8A of the Act against the Company or related to
the offering has been initiated or threatened by the Commission and no notice of objection of the Commission to the use of such Registration Statement pursuant to Rule 401(g)(2) under the Act has been received by the Company. Any reference herein to
the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Registration Statement, the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement shall be deemed to refer to and include the documents incorporated by
reference therein pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> which were filed under the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively, the &#147;<B>Exchange
Act</B>&#148;) on or before the Effective Date of the Registration Statement or the issue date of the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement, as the case may be; and any reference herein to the
terms &#147;amend,&#148; &#147;amendment&#148; or &#147;supplement&#148; with respect to the Registration Statement, the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement shall be deemed to refer to and
include the filing of any document under the Exchange Act after the Effective Date of the Registration Statement or the issue date of the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement, as the case may be,
deemed to be incorporated therein by reference. Certain terms used herein are defined in Section&nbsp;14 hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) On each Effective
Date, the Registration Statement did, and when the Final Prospectus Supplement is first filed in accordance with Rule 424(b) and on the Closing Date, the Final Prospectus Supplement (and any amendment or supplement thereto) will, comply in all
material respects with the applicable requirements of the Act and the Exchange Act and the respective rules thereunder; on each Effective Date and at the Execution Time, the Registration Statement did not and will not contain any untrue statement of
a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading; and on the date of any filing pursuant to Rule 424(b); and on the Closing Date, the Final
Prospectus Supplement (together with any amendment or supplement thereto) will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; provided, however, that the Company makes no representations or warranties as to the information contained in or omitted from the Registration Statement or the Final Prospectus Supplement (or any amendment
or supplement thereto) in reliance upon and in conformity with information furnished in writing to the Company by the Placement Agents specifically for inclusion in the Registration Statement or the Final Prospectus Supplement (or any amendment or
supplement thereto), it being understood and agreed that the only such information furnished by the Placement Agents consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As of the Initial Sale Time, the Pricing Disclosure Package, when taken together as a whole with the pricing information set forth in
Exhibit B hereto, does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The
preceding sentence does not apply to statements in or omissions from the Pricing Disclosure Package based upon and in conformity with written information furnished to the Company by the Placement Agents specifically for use therein, it being
understood and agreed that the only such information furnished by or on behalf of the Placement Agents consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;(i) At the earliest time after the filing of the Registration Statement that the Company or another offering participant made a
<I>bona fide</I> offer (within the meaning of Rule 164(h)(2)) of the Shares and (ii)&nbsp;as of the Execution Time (with such date being used as the determination date for purposes of this clause (ii)), the Company was not and is not an Ineligible
Issuer (as defined in Rule 405), without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an Ineligible Issuer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Prior to the execution of this Agreement, the Company has not, directly or indirectly,
offered or sold any of the Shares by means of any &#147;prospectus&#148; (within the meaning of the Act) or used any &#147;prospectus&#148; (within the meaning of the Act) in connection with the offer or sale of the Shares, in each case other than
the Registration Statement, any Preliminary Prospectus Supplement and the Final Prospectus Supplement. The Company represents and agrees that it has not and, unless it obtains the prior consent of the Placement Agents, it will not make any offer
relating to the Shares that would constitute an &#147;Issuer Free Writing Prospectus&#148; or that would otherwise constitute a &#147;Free Writing Prospectus&#148; other than any Permitted Free Writing Prospectus. Any such Free Writing Prospectus
relating to the Shares consented to by the Placement Agents is hereinafter referred to as a &#147;<B>Permitted Free Writing Prospectus.</B>&#148; The Company has complied and will comply in all material respects with the requirements of Rule 433
under the Act applicable to any Permitted Free Writing Prospectus, including timely filing with the Commission where required, legending and record keeping. Each Permitted Free Writing Prospectus does not conflict with the information contained in
the Registration Statement or the Pricing Disclosure Package did not and on the Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading; <I>provided, however</I>, that the Company makes no representations or warranties as to the information contained in or omitted from such Permitted Free Writing Prospectus in reliance
upon and in conformity with information furnished in writing to the Company by the Placement Agents specifically for inclusion in such Permitted Free Writing Prospectus, it being understood and agreed that the only such information furnished by the
Placement Agents consists of the information described as such in Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) All statistical, demographic and
market-related data included in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in
all material respects or represent the Company&#146;s good faith estimates that are made on the basis thereof. To the extent required, the Company has obtained the written consent for the use of such data from such sources. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, the
Company has established and maintains disclosure controls and procedures (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act), which (i)&nbsp;are designed to
ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&#146;s principal executive officer and its principal financial officer by others within those entities, within the time
periods specified in the Commission&#146;s rules and forms; (ii)&nbsp;have been evaluated by management of the Company for effectiveness as of the end of the Company&#146;s most recent fiscal quarter; and (iii)&nbsp;are effective in all material
respects to perform the functions for which they were established. Since the end of the Company&#146;s most recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company&#146;s internal control over
financial reporting (whether or not remediated) and no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over
financial reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the
Company&#146;s internal control over financial reporting </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) This Agreement has been duly authorized, executed and delivered by the
Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Shares have been duly authorized for issuance and sale pursuant to this Agreement and, when issued and delivered by the
Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and, except as described in Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, the issuance
and sale of the Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Except otherwise disclosed in the Registration Statement, the Pricing Disclosure Package
and the Final Prospectus Supplement, there are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this
Agreement, except for such rights as have been duly waived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Except as otherwise disclosed in the Registration Statement, the Pricing
Disclosure Package and the Final Prospectus Supplement, subsequent to the respective dates as of which information is given in the Registration Statement and the Prospectus: (i)&nbsp;there has been no material adverse change, or any development that
could be reasonably expected to result in a material adverse change, in (A)&nbsp;the condition, financial or otherwise, or in the earnings, business, properties, operations, operating results, assets, liabilities or prospects, whether or not arising
from transactions in the ordinary course of business, of the Company and its subsidiaries, considered as one entity or (B)&nbsp;the ability of the Company to consummate the transactions contemplated by this Agreement or perform its obligations
hereunder (any such change being referred to herein as a &#147;<B>Material Adverse Change</B>&#148;); ii) the Company and its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct or
contingent, including without limitation any losses or interference with their business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or
governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, and have not entered into any transactions not in the ordinary course of business; and
(iii)&nbsp;there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company or its subsidiaries and there has been no dividend or distribution of any kind declared,
paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Company&#146;s subsidiaries on any class of capital stock, or any repurchase or redemption by the Company or any of its subsidiaries of any
class of capital stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) Ernst&nbsp;&amp; Young LLP, which has expressed its opinion with respect to the financial statements (which
term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement, the Base Prospectus and the Final Prospectus Supplement, is (i)&nbsp;an independent registered public accounting
firm as required by the Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (&#147;<B>PCAOB</B>&#148;), (ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule <FONT
STYLE="white-space:nowrap">2-01</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Act and (iii)&nbsp;a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who
has not requested such registration to be withdrawn. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) The financial statements filed with the Commission as a part of the Registration
Statement, the Pricing Disclosure Package and the Final Prospectus Supplement present fairly in all material respects the consolidated financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of
their operations, changes in stockholders&#146; equity and cash flows for the periods specified. Such financial statements have been prepared in conformity with generally accepted accounting principles applied on a consistent basis throughout the
periods involved, except as may be expressly stated in the related notes thereto. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and
the Final Prospectus Supplement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto in all material respects. No other financial
statements or supporting schedules are required to be included in the Registration Statement, the Pricing Disclosure Package or the Final Prospectus Supplement. The financial data set forth in each of the Registration Statement, the Pricing
Disclosure Package and the Final Prospectus Supplement under the caption &#147;Selected Financial Data&#148; fairly present in all material respects the information set forth therein on a basis consistent with that of the audited financial
statements contained in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) Except as otherwise disclosed in the Registration Statement, the Pricing Disclosure
Package and the Final Prospectus Supplement, the Company and each of its subsidiaries make and keep accurate books and records and maintain a system of internal accounting controls sufficient to provide reasonable assurance that:
(i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted
accounting principles as applied in the United States and to maintain accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded
accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;the interactive data in eXtensible Business Reporting Language included or incorporated
by reference in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#146;s rules and
guidelines applicable thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) The Company has been duly incorporated and is validly existing as a corporation in good standing under
the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the Pricing Disclosure Package and the Final
Prospectus Supplement and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing in the State of Texas and each other jurisdiction in which
the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not result in a Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) Each of the Company&#146;s &#147;subsidiaries&#148; (for purposes of this Agreement, as defined in Rule 405 under the Act) has been duly
incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the
power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement. Each of the Company&#146;s
subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of
property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not result in a Material Adverse Change. All of the issued and outstanding capital stock or other equity or ownership
interests of each of the Company&#146;s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and, except as otherwise disclosed in the Prospectus, are owned by the Company, directly or through subsidiaries,
free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. The Company does not own or control, directly or indirectly, any corporation, association or other entity that would constitute a significant subsidiary
as defined under Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> other than the subsidiaries listed in Exhibit 21 to the Company&#146;s most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) The authorized, issued and outstanding capital stock of the Company is as set forth in the
Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement under the caption &#147;Capitalization&#148; (other than for subsequent issuances, if any, pursuant to employee benefit plans or upon the exercise of
outstanding options or warrants, in each case described in the Registration Statement and the Prospectus). The Common Stock (including the Shares) conform in all material respects to the description thereof contained in the Registration Statement,
the Pricing Disclosure Package and the Final Prospectus Supplement. All of the issued and outstanding Common Stock have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all federal and
state securities laws. None of the outstanding Common Stock was issued in violation of any preemptive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights
of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than those described in the Registration Statement, the
Pricing Disclosure Package and the Final Prospectus Supplement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) The Common Stock are registered pursuant to Section&nbsp;12(b) or
12(g) of the Exchange Act and are listed on the Nasdaq Global Select Market (&#147;<B>Nasdaq</B>&#148;), and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock
under the Exchange Act or delisting the Common Stock from Nasdaq, nor has the Company received any notification that the Commission or Nasdaq is contemplating terminating such registration or listing. To the Company&#146;s knowledge, it is in
compliance in all material respects with all applicable listing requirements of Nasdaq. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) Neither the Company nor any of its
subsidiaries is in violation of its charter or by laws, partnership agreement or operating agreement or similar organizational documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default)
(&#147;<B>Default</B>&#148;) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other instrument
or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective properties or assets are subject,
except for such Defaults as could not be expected, individually or in the aggregate, to result in a Material Adverse Change. The Company&#146;s execution, delivery and performance of this Agreement, consummation of the transactions contemplated
hereby and the issuance and sale of the Shares will not contravene (i)&nbsp;the provisions of the charter or by laws, partnership agreement or operating agreement or similar organizational documents, as applicable, of the Company or any subsidiary,
(ii)&nbsp;any agreement or other instrument binding upon the Company or any of its subsidiaries that is material to the Company and its subsidiaries, taken as a whole, and (iii)&nbsp;any law, administrative regulation or administrative or court
decree applicable to the Company or any of its subsidiaries; except, in the case of clauses (ii)&nbsp;and (iii), as would not reasonably be expected to result in a Material Adverse Change. No consent, approval, authorization or other order of, or
registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Company&#146;s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby, except
such as (i)&nbsp;have been obtained or made by the Company and are in full force and effect under the Act, (ii)&nbsp;as may be required under applicable state securities or blue sky laws or FINRA (as defined below) and (iii)&nbsp;if not obtained,
have not or would not reasonably be expected to result in a Material Adverse Change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) Except as otherwise disclosed in the Registration
Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, there is no action, suit, proceeding, inquiry or investigation brought by or before any legal or governmental entity now pending or, to the knowledge of the Company,
threatened, against or affecting the Company or any of its subsidiaries, which could be expected, individually or in the aggregate, to result in a Material Adverse Change. No material labor dispute with the employees of the Company exists, except as
described in the Prospectus, or, to the knowledge of the Company, is imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors
that could result in a Material Adverse Change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u) Except as otherwise disclosed in the Registration Statement, the Pricing Disclosure
Package and the Final Prospectus Supplement, the Company and its subsidiaries own, or have rights to use the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property
described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement as being owned or licensed by them or which are used in and necessary for the conduct of their respective businesses as currently conducted
or as currently proposed to be conducted (collectively, &#147;<B>Intellectual Property</B>&#148;) and, to the Company&#146;s knowledge, the conduct of their respective businesses does not and will not infringe or misappropriate in any material
respect any such rights of others. The Intellectual Property owned by the Company has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part, and the Company is unaware of any facts which would
form a reasonable basis for any such adjudication. To the Company&#146;s knowledge: (i)&nbsp;except as otherwise disclosed in the Prospectus and with respect to LX9211 (to which the Company owns an exclusive license), there are no third parties who
have ownership, royalty, or exclusive license rights to any Intellectual Property owned by the Company, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration
Statement, the Pricing Disclosure Package and the Final Prospectus Supplement as licensed to the Company or one or more of its subsidiaries; and (ii)&nbsp;there is no material infringement by third parties of any Intellectual Property owned by the
Company. There is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others: (A)&nbsp;challenging the Company&#146;s rights in or to any Intellectual Property licensed to the Company; (B)&nbsp;challenging
the validity, enforceability or scope of any Intellectual Property owned by the Company; or (C)&nbsp;asserting that the Company or any of its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or
service described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement as under development, infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret or other
intellectual rights of others. The Company and its subsidiaries have materially complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any subsidiary, and all such agreements are, to the
Company&#146;s knowledge, in full force and effect. To the Company&#146;s knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual Property. The Company and its subsidiaries have taken
reasonable steps to protect, maintain and safeguard Intellectual Property owned by the Company, including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their
employees, and, to the Company&#146;s knowledge, no employee of the Company is in or has been in violation of any term of any such agreement. The duty of candor and good faith as required by the United States Patent and Trademark Office during the
prosecution of the United States patents and patent applications included in the Intellectual Property owned by the Company have been materially complied with; and in all foreign offices having similar requirements, all such requirements have been
materially complied with. The product candidates described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement as under development by the Company or any subsidiary fall within the scope of the claims of
one or more patents owned by, or exclusively licensed to, the Company or any subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) Except as otherwise disclosed in the
Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, the Company and each subsidiary possess such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory
agencies or bodies to conduct their respective businesses as currently conducted and as described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement (&#147;<B>Permits</B>&#148;), except as would not
reasonably be expected to result in a Material Adverse Change, and the Company has not received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit which, singly or in the aggregate,
if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(w) Except as otherwise disclosed in the Registration Statement, the Pricing Disclosure
Package and the Final Prospectus Supplement, the Company and its subsidiaries have good and marketable title to all of the real and personal property and other assets owned by them which is material to the business of the Company, in each case free
and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects except as do not materially affect the value of such property and do not interfere in any material respect with the use made and
currently proposed to be made of such property by the Company. Except as otherwise disclosed in the Prospectus, the real property, improvements, equipment and personal property held under lease by the Company or any of its subsidiaries are held
under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company or such
subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) Except as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change, the
Company and its subsidiaries (i)&nbsp;have filed all necessary federal, state and foreign income and franchise tax returns or have properly requested extensions thereof and (ii)&nbsp;have paid all taxes required to be paid by any of them and, if due
and payable, any related or similar assessment, fine or penalty levied against any of them, except as may be being contested in good faith and by appropriate proceedings and for which adequate reserves are maintained in accordance with generally
accepted accounting principles. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(y) The Company is not, and will not be, either after receipt of payment for the Shares or after the
application of the proceeds therefrom as described under &#147;Use of Proceeds&#148; in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, required to register as an &#147;investment company&#148; under
the Investment Company Act of 1940, as amended (the &#147;<B>Investment Company Act</B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(z) The Company is insured by insurers of
recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which it is engaged. The Company has no reason to believe that it will not be able to renew its existing
insurance coverage as and when such coverage expires or obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not result in a Material Adverse Change, except as described in the Prospectus.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(aa) Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action designed to or that reasonably would be
expected to cause or result in stabilization or manipulation of the price of the Common Stock or of any &#147;reference security&#148; (as defined in Rule 100 of Regulation M under the Exchange Act (&#147;<B>Regulation M</B>&#148;)) with respect to
the Common Stock, whether to facilitate the sale or resale of the Shares or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(bb) There are no business relationships or
related-party transactions involving the Company or any of its subsidiaries or any other person required to be described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement which have not been described
as required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(cc) All of the information provided to the Placement Agents or to counsel for the Placement Agents by the Company, its
counsel, its officers and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Shares is true, complete and correct. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(dd) Except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, neither
the Company nor any of its subsidiaries nor, to the best of the Company&#146;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or
foreign office in violation of any law or of the character required to be disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ee) Except as described in the Registration Statement, the Pricing Disclosure Package and
the Final Prospectus Supplement and except as could not be expected, individually or in the aggregate, to result in a Material Adverse Change, (i)&nbsp;neither the Company nor any of its subsidiaries is in violation of any applicable federal, state,
local or foreign statute, law (including fundamental principles of common law), rule, regulation or ordinance, including any judicial or administrative interpretation thereof, relating to pollution or protection of human health (to the extent
relating to exposure to Hazardous Materials, defined below), the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations
relating to the release of pollutants, contaminants, or hazardous or toxic wastes or substances that are subject to regulation by any governmental authority (collectively, &#147;<B>Hazardous Materials</B>&#148;) or to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#147;<B>Environmental Laws</B>&#148;), (ii) the Company and its subsidiaries have all permits, authorizations and approvals required of
them under Environmental Laws for their operations has currently conducted and are each in compliance with the terms and conditions of such permits, authorizations and approvals, and (iii)&nbsp;the Company and its subsidiaries has not received
written notice of any pending or threatened liability under any Environmental Law and, to the knowledge of the Company, there is no event or occurrence that would reasonably be expected to result in the receipt of any such notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ff) Except as would not, individually or in the aggregate, result in a Material Adverse Change: (i)&nbsp;the Company and its subsidiaries and
any &#147;employee benefit plan&#148; (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &#147;<B>ERISA</B>&#148;)) established or maintained
by the Company, its subsidiaries or their &#147;ERISA Affiliates&#148; (as defined below) are in compliance in all material respects with ERISA; &#147;<B>ERISA</B><B><I> </I></B><B>Affiliate</B>&#148; means, with respect to the Company or any of its
subsidiaries, any member of any group of organizations described in Sections 414(b), (c), (m) or (o)&nbsp;of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the &#147;<B>Code</B>&#148;) of
which the Company or such subsidiary is a member; (ii)&nbsp;no &#147;reportable event&#148; (as defined under ERISA), other than an event for which the <FONT STYLE="white-space:nowrap">30-day</FONT> notice period is waived, has occurred or is
reasonably expected to occur with respect to any &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates; (iii)&nbsp;no &#147;employee benefit plan&#148; established or maintained
by the Company, its subsidiaries or any of their ERISA Affiliates, if such &#147;employee benefit plan&#148; were terminated, would have any &#147;amount of unfunded benefit liabilities&#148; (as defined under ERISA); (iv) neither the Company, its
subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (a)&nbsp;Title IV of ERISA with respect to termination of, or withdrawal from, any &#147;employee benefit plan&#148; or (b)&nbsp;Sections
412, 4971, 4975 or 4980B of the Code; and (v)&nbsp;each &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to be qualified under Section&nbsp;401(a) of the
Code is so qualified and nothing has occurred, whether by action or failure to act, which would reasonably be expected to cause the loss of such qualification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(gg) Except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, there is
no broker, finder or other party that is entitled to receive from the Company any brokerage or finder&#146;s fee or other fee or commission as a result of any transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(hh) Except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, the
Company and its subsidiaries are in compliance with all applicable laws, rules and regulations, except where failure to be so in compliance could not be expected, individually or in the aggregate, to result in a Material Adverse Change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company,
any director, officer, or employee of the Company or any of its subsidiaries, nor to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for,
or on behalf of, the Company or any of its subsidiaries (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii)&nbsp;made or taken any act in furtherance of
an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or public international organization, or any
political party, party official, or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#147;<B>FCPA</B>&#148;), the UK Bribery Act 2010, or any
other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, authorized, requested, or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit. The
Company and its subsidiaries and, to the knowledge of the Company, the Company&#146;s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and
which are reasonably expected to continue to ensure, continued compliance therewith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(jj) The operations of the Company and its
subsidiaries are, and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all
applicable jurisdictions, the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<B>Money Laundering
Laws</B>&#148;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the
best knowledge of the Company, threatened. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(kk) The preclinical tests and clinical trials, and other studies (collectively,
&#147;studies&#148;) that are described in, or the results of which are referred to in, the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement were and, if still pending, are, to the Company&#146;s knowledge,
being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being
developed by the Company; the descriptions of the results of such studies do not contain any misstatement of a material fact or omit to state a material fact necessary to make such statements not misleading, and the Company and its subsidiaries have
no knowledge of any other studies the results of which reasonably call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement; the Company and its
subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government
or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the &#147;<B>Regulatory Agencies</B>&#148;) except where failure to do so would not result in a Material Adverse Change; neither the
Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or material modification of any clinical trials that are described or referred to in the Registration
Statement, the Pricing Disclosure Package and the Final Prospectus Supplement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ll) Neither the Company nor any of its subsidiaries, nor,
to the knowledge of the Company, directors, officers, or employees, nor, to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any
U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#147;<B>OFAC</B>&#148;) or the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty&#146;s
Treasury of the United Kingdom, or other relevant sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;); nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the
target of Sanctions, including, without limitation, Crimea, Cuba, Iran, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
North Korea, and Syria; and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any
joint venture partner or other person or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that at the time of such financing, is the subject or the target of Sanctions or in any
other manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the past five years, the Company and its
subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned
Country. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(mm) The Company is in compliance, in all material respects, with all applicable provisions of the Sarbanes-Oxley Act of 2002 and
the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(nn) The Company&#146;s and its subsidiaries&#146; information technology assets and
equipment, computers, systems, networks, hardware, and databases (collectively, &#147;<B>IT Systems</B>&#148;) are reasonably adequate for the operation of the business of the Company and its subsidiaries as currently conducted. The Company and its
subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, operation,
redundancy and security of all IT Systems and data, including &#147;Personal Data,&#148; used in connection with their businesses. &#147;<B>Personal Data</B>&#148; means (i)&nbsp;a natural person&#146;s name, street address, telephone number, <FONT
STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number, passport number, credit card number, or bank account information; (ii)&nbsp;any information which would
qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; (iii) &#147;personal data&#148; as defined by GDPR (as defined below); (iv) any information which would qualify as &#147;protected health
information&#148; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#147;<B>HIPAA</B>&#148;); and (v)&nbsp;any other piece of
information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person&#146;s health or sexual orientation. In the past three (3)&nbsp;years, there
have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person under Privacy Laws (as defined below). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(oo) The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable state and federal data
privacy and security laws and regulations, including without limitation HIPAA, and the Company and its subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May&nbsp;25, 2018, have been and currently are in
material compliance with, the European Union General Data Protection Regulation (&#147;<B>GDPR</B>&#148;) (EU 2016/679) (collectively, the &#147;<B>Privacy Laws</B>&#148;). To ensure compliance with the Privacy Laws, the Company and its subsidiaries
have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with the Company&#146;s policies and procedures relating to data privacy and security and the collection, storage, use,
disclosure, handling, and analysis of Personal Data (the &#147;<B>Policies</B>&#148;). The Company further certifies that neither it nor any subsidiary: (i)&nbsp;has received written notice of any actual or potential liability under or relating to,
or actual or potential violation of, any of the Privacy Laws; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action initiated by a governmental authority pursuant to any
Privacy Law; or (iii)&nbsp;is a party to any order, decree, or settlement agreement issued by a governmental authority that imposes any obligation or liability under any Privacy Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(pp) The Company and its subsidiaries are, and at all times have been, in compliance with
all applicable Health Care Laws, except to the extent that any <FONT STYLE="white-space:nowrap">non-compliance</FONT> would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change. For purposes of this
Agreement, &#147;<B>Health Care Laws</B>&#148; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301 et seq.), the Public Health Service Act (42 U.S.C. Section&nbsp;201 et seq.), and the regulations promulgated
thereunder; (ii)&nbsp;all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the Civil
False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal false statements law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under
HIPAA (42 U.S.C. Section&nbsp;1320d et seq.), the Stark Law (42 U.S.C. Section&nbsp;1395nn), the civil monetary penalties law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7a),</FONT> the exclusion law (42 U.S.C. <FONT
STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the Physician Payments Sunshine Act (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320-7h),</FONT> and applicable laws governing government funded or sponsored healthcare programs;
(iii)&nbsp;HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education
Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; and (vi)&nbsp;all other local, state, federal, national, supranational and foreign
laws, relating to the regulation of the Company or its subsidiaries, and (vii)&nbsp;the directives and regulations promulgated pursuant to such statutes and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof. Neither
the Company nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or
third party alleging that any product operation or activity is in violation of any Health Care Laws nor, to the Company&#146;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action
threatened, except in each case as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments
were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring
agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its subsidiaries nor, to the knowledge of the Company, any of their
respective employees, officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental
inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(qq) Any certificate signed by any officer of the Company and delivered to the Placement Agents or counsel for the Placement Agents in
connection with the offering of the Shares shall be deemed a representation and warranty by the Company, as to matters covered thereby, to the Placement Agents, as applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Certain Covenants of the Company</U>. The Company hereby agrees with each Placement Agent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) During the Prospectus Delivery Period, before using or filing any Permitted Free Writing Prospectus and before using or filing any
amendment or supplement to the Registration Statement, the Final Prospectus Supplement or any Permitted Free Writing Prospectus (in each case, other than due to the filing of an Incorporated Document), to furnish to the Placement Agents, upon such
party&#146;s request, a copy of each such proposed Permitted Free Writing Prospectus, amendment or supplement within a reasonable period of time before filing with the Commission or using any such Permitted Free Writing Prospectus, amendment or
supplement and the Company will not use or file any such Permitted Free Writing Prospectus or any such proposed amendment or supplement to which any of the Placement Agents reasonably objects, unless the Company&#146;s legal counsel has advised the
Company that use or filing of such document is required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To file the Final Prospectus Supplement within the time period required by Rule 424(b)
under the Act (without reference to Rule 424(b)(8)) and to file any Permitted Free Writing Prospectus to the extent required by Rule 433 under the Act and to provide copies of any Preliminary Prospectus Supplement, the Final Prospectus Supplement,
any other amendments or supplements to the Final Prospectus Supplement and each Permitted Free Writing Prospectus (to the extent not previously delivered or filed on the Commission&#146;s Electronic Data Gathering, Analysis and Retrieval system or
any successor system thereto (collectively, &#147;<B>EDGAR</B>&#148;)) to the Placement Agents, upon request of such party, via <FONT STYLE="white-space:nowrap">e-mail</FONT> in &#147;.pdf&#148; format on such filing date to an <FONT
STYLE="white-space:nowrap">e-mail</FONT> account designated by the Placement Agents and, at the relevant party&#146;s request, to also furnish copies of any Preliminary Prospectus Supplement, the Final Prospectus Supplement, any other amendments or
supplements to the Final Prospectus Supplement and each Permitted Free Writing Prospectus to each exchange or market on which sales were effected as may be required by the rules or regulations of such exchange or market. To file timely all reports
and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act during the Prospectus Delivery Period, and during such same period to
advise the Placement Agents promptly after the Company receives notice thereof, (i)&nbsp;when the Final Prospectus Supplement, and any amendment or supplement thereto, shall have been filed (if required) with the Commission pursuant to Rule 424(b)
under the Act; (ii)&nbsp;when, prior to the termination of the offering of the Shares, any amendment to the Registration Statement has been filed or has become effective (iii)&nbsp;of the issuance by the Commission of any stop order or any order
preventing or suspending the use of any prospectus relating to the Shares or the initiation or threatening of any proceeding for that purpose, pursuant to Section&nbsp;8A of the Act; (iv)&nbsp;of any objection by the Commission to the use of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> by the Company pursuant to Rule 401(g)(2) under the Act; (v)&nbsp;of the suspension of the qualification of the Shares for offering or sale in any jurisdiction or of the initiation or threatening in writing of
any proceeding for any such purpose; (vi)&nbsp;of any request by the Commission for the amendment of the Registration Statement or the amendment or supplementation of the Final Prospectus Supplement (in each case including any documents incorporated
by reference therein) or for additional information; (vii)&nbsp;of the occurrence of any event, as a result of which the Final Prospectus Supplement or any Permitted Free Writing Prospectus as then amended or supplemented includes any untrue
statement of a material fact or omits to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances existing when the Final Prospectus Supplement or any such Permitted
Free Writing Prospectus is delivered to a purchaser, not misleading; and (viii)&nbsp;of the receipt by the Company of any notice of objection of the Commission to the use of the Registration Statement or any post-effective amendment thereto; and in
the event of the issuance of any such stop order or of any such order preventing or suspending the use of any such prospectus or suspending any such qualification, or of any notice of objection pursuant to Rule 401(g)(2) under the Act, to use
promptly its commercially reasonable efforts to obtain its withdrawal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Upon request, the Company will furnish to the Placement Agents
and counsel for the Placement Agents, without charge, signed copies of the Registration Statement (including exhibits thereto) and, during the Prospectus Delivery Period, as many copies of each Base Prospectus, the Final Prospectus Supplement and
each Permitted Free Writing Prospectus and any amendment or supplement thereto as the Placement Agents may reasonably request; provided, however, that the Company shall have no obligation to provide the Placement Agents with any document filed on
EDGAR or included on the Company&#146;s Internet website. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Upon request, during the Prospectus Delivery Period, to furnish or make available to the
Placement Agents (i)&nbsp;copies of any reports or other communications which the Company shall send to its shareholders or shall from time to time publish or publicly disseminate and (ii)&nbsp;copies of all annual, quarterly and current reports
filed with the Commission on Forms <FONT STYLE="white-space:nowrap">10-K,</FONT> <FONT STYLE="white-space:nowrap">10-Q</FONT> and <FONT STYLE="white-space:nowrap">8-K,</FONT> or such other similar form as may be designated by the Commission, and to
furnish to the Placement Agents, as applicable, from time to time such other information as the Placement Agents may reasonably request regarding the Company or its subsidiaries, in each case as soon as such reports, communications, documents or
information becomes available or promptly upon the request of the Placement Agents, as applicable; provided, however, that the Company shall have no obligation to provide the Placement Agents with any document filed on EDGAR or included on the
Company&#146;s Internet website. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) If, at any time during the Prospectus Delivery Period, any event shall occur or condition shall exist
as a result of which it is necessary in the reasonable opinion of counsel for the Placement Agents or counsel for the Company, to further amend or supplement the Final Prospectus Supplement or any Permitted Free Writing Prospectus as then amended or
supplemented in order that the Final Prospectus Supplement or any such Permitted Free Writing Prospectus will not include an untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order
to make the statements therein not misleading, in light of the circumstances existing at the time the Final Prospectus Supplement or any such Permitted Free Writing Prospectus is delivered to a purchaser, or if it shall be necessary, in the
reasonable opinion of either such counsel, to amend or supplement the Registration Statement, the Final Prospectus Supplement or any Permitted Free Writing Prospectus in order to comply with the requirements of the Act, in the case of such a
determination by counsel to the Company, immediate notice shall be given, and confirmed in writing, to the Placement Agents and, in either case, the Company will, subject to Section&nbsp;1(a) above, promptly prepare and file with the Commission such
amendment or supplement, whether by filing documents pursuant to the Act, the Exchange Act or otherwise, as may be necessary to correct such untrue statement or omission or to make the Registration Statement, the Final Prospectus Supplement or any
such Permitted Free Writing Prospectus comply with such requirements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) To generally make available to its security holders and the
Placement Agents as soon as reasonably practicable, but not later than 16 months after the first day of each fiscal quarter referred to below, an earnings statement (in form complying with the provisions of Section&nbsp;11(a) under the Act and Rule
158 of the Commission promulgated thereunder) covering each twelve-month period beginning, in each case, not later than the first day of the Company&#146;s fiscal quarter next following the &#147;effective date&#148; (as defined in such Rule 158) of
the Registration Statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) To apply the net proceeds from the sale of the Shares in the manner described in the Final Prospectus
Supplement under the caption &#147;Use of Proceeds.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Not to, and to cause its subsidiaries not to, take, directly or indirectly,
any action designed to cause or result in, or that constitutes or might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Shares; provided that
nothing herein shall prevent the Company from filing or submitting reports under the Exchange Act or issuing press releases in the ordinary course of business. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each Permitted Free Writing Prospectus that
is not filed with the Commission in accordance with Rule 433 under the Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Conditions of Placement Agents&#146; Obligations</U>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The obligations of the Placement Agents hereunder are subject to the performance by the Company of its covenants and other obligations
hereunder and to the following additional conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Final Prospectus Supplement shall have been filed with the Commission
pursuant to Rule 424(b) at or before 5:30 p.m., New York City time, on the second full business day after the date of this Agreement (or such earlier time as may be required under the Securities Act). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The respective representations and warranties of the Company contained herein shall be
true and correct on the date hereof and on and as of the Closing Date and the statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Prior to the Closing: (i)&nbsp;no stop order suspending the effectiveness of the Registration Statement shall have been issued under the
Securities Act and no proceedings initiated under Section&nbsp;8(d) or 8(e) of the Securities Act for that purpose or pursuant to Section&nbsp;8A of the Securities Act shall be pending or threatened by the Commission, and (ii)&nbsp;any request for
additional information on the part of the Commission (to be included in the Registration Statement, the Pricing Disclosure Package, the Final Prospectus Supplement or any Issuer Free Writing Prospectus or otherwise) shall have been complied with to
the reasonable satisfaction of the Placement Agents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) No event or condition of a type described in Section&nbsp;2(k) hereof shall have
occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Final Prospectus Supplement (excluding any amendment or supplement thereto) and the effect
of which in the judgment of the Placement Agents makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date on the terms and in the manner contemplated by this Agreement, the Pricing
Disclosure Package and the Final Prospectus Supplement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company shall have furnished to the Placement Agents a certificate of the
Company, signed by the Chief Executive Officer, President or Chief Financial Officer of the Company, dated the Closing Date, to the effect that he or she has carefully examined the Registration Statement, the Pricing Disclosure Package and the Final
Prospectus Supplement, any supplements or amendments thereto and this Agreement and that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the representations and warranties of the Company in this Agreement are true and correct on and as of the
Closing Date with the same effect as if made on such date and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to the Closing Date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no stop order suspending the effectiveness of the Registration Statement or notice by the Commission objecting
to its use has been issued and no proceedings for that purpose have been instituted or, to the Company&#146;s knowledge, threatened; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">since the date of the most recent financial statements included or incorporated by reference in the Base
Prospectus and the Final Prospectus Supplement (exclusive of any amendment or supplement thereto), there has been no material adverse effect on the condition (financial or otherwise), prospects, earnings, business or properties of the Company and
its subsidiaries, taken as a whole, whether or not arising from transactions in the ordinary course of business, except as set forth in or contemplated in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement
(exclusive of any amendment or supplement thereto). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Company shall have requested and caused Ernst&nbsp;&amp; Young LLP to have furnished
to the Placement Agents, on the date of this Agreement and at the Closing Date, comfort letters, dated respectively as of the date of this Agreement and the Closing Date in form and substance satisfactory to the Placement Agents, including
confirmation that (i)&nbsp;they are an independent registered public accounting firm with respect to the Company within the meaning of the Act and the applicable rules and regulations thereunder adopted by the Commission and the Public Company
Accounting Oversight Board (United States) (&#147;<B>PCAOB</B>&#148;) and (ii)&nbsp;they have performed an audit of the consolidated financial statements of the Company as of December&nbsp;31, 2019 and 2018, and for each of the three years in the
period ended December&nbsp;31, 2019, and the related financial statement schedule. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The Company shall have requested and caused to be
delivered (i)&nbsp;an opinion of Brian T. Crum, Vice President and General Counsel of the Company, (ii)&nbsp;an opinion, and, if not covered in such opinion, a negative assurance letter of Vinson&nbsp;&amp; Elkins LLP, counsel for the Company, and
(iii)&nbsp;an opinion with respect to intellectual property matters of Max Bachrach, Ph.D., Vice President, Intellectual Property, of the Company, in each case addressed to each of the Placement Agents and dated the Closing Date, in form and
substance satisfactory to the Placement Agents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The Placement Agents shall have received from Cooley LLP, counsel for the Placement
Agents, such letter and opinion or opinions dated the Closing Date, addressed to each of the Placement Agents and addressing such matters as the Placement Agents may reasonably require, and the Company shall have furnished to such counsel such
documents as they request for the purpose of enabling them to pass upon such matters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Subsequent to the earlier of (i)&nbsp;the
Initial Sale Time and (ii)&nbsp;the execution and delivery of this Agreement, (A)&nbsp;no downgrading shall have occurred in the rating accorded any debt securities, convertible securities or preferred stock issued, or guaranteed by, the Company or
any of its subsidiaries by any &#147;nationally recognized statistical rating organization,&#148; as such term is defined under Section&nbsp;3(a)(62) under the Exchange Act and (B)&nbsp;no such organization shall have publicly announced that it has
under surveillance or review, or has changed its outlook with respect to, its rating of any such debt securities or preferred stock issued or guaranteed by the Company or any of its subsidiaries (other than an announcement with positive implications
of a possible upgrading). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) The Company shall have filed with Nasdaq a Notification of Listing of Additional Shares with respect to the
Shares and Nasdaq shall not have objected thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Prior to the Closing Date, the Company shall have furnished to the Placement Agents
such further information, certificates and documents as the Placement Agents may reasonably request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the conditions specified
in this Section&nbsp;4 shall not have been fulfilled when and as provided in this Agreement, or if any of the opinions and certificates mentioned above or elsewhere in this Agreement shall not be reasonably satisfactory in form and substance to the
Placement Agents, this Agreement and all obligations of the Placement Agents hereunder may be canceled at, or at any time prior to, the Closing Date. Notice of such cancellation shall be given to the Company in writing or by telephone or facsimile
confirmed in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The documents required to be delivered by this Section&nbsp;4 shall be delivered by email exchange on the Closing
Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Effectiveness of Agreement</U>. This Agreement shall become effective as of the date
first written above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Termination</U>. This Agreement shall be subject to termination in the absolute discretion of the Placement
Agents, by notice given to the Company if after the execution and delivery of this Agreement and on or prior to the Closing Date (i)&nbsp;trading in the Company&#146;s Common Stock shall have been suspended by the Commission or Nasdaq or trading in
securities generally on Nasdaq shall have been suspended or limited or minimum prices shall have been established on such exchange, (ii)&nbsp;a banking moratorium shall have been declared either by Federal or New York State authorities, (iii)&nbsp;a
material disruption has occurred in commercial banking or securities settlement or clearance services in the United States or (iv)&nbsp;there shall have occurred any outbreak or escalation of hostilities, declaration by the United States of a
national emergency or war, or other calamity or crisis the effect of which on financial markets is such as to make it, in the sole judgment of the Placement Agents, impractical or inadvisable to proceed with the offering, sale or delivery of the
Shares on the Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Purchase Agreements, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Indemnity and Contribution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to indemnify and hold harmless each Placement Agent, the directors, officers, employees, affiliates and agents of each
Placement Agent and each person who controls any Placement Agent within the meaning of either the Act or the Exchange Act against any and all losses, claims, damages or liabilities, joint or several, to which they or any of them may become subject
under the Act, the Exchange Act or other Federal or state statutory law or regulation, at common law or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of, or are based upon any untrue
statement or alleged untrue statement of a material fact contained in the Registration Statement for the registration of the Shares as originally filed or in any amendment thereof, or in the Final Prospectus Supplement (or any amendment or
supplement thereto), any Preliminary Prospectus Supplement, any Issuer Free Writing Prospectus, any road show as defined in Rule 433(h) under the Securities Act (a &#147;road show&#148;) or any Pricing Disclosure Package (including any Pricing
Disclosure Package that has subsequently been amended), or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and
agrees to reimburse each such indemnified party, as incurred, for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the
Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any such untrue statement or omission or alleged untrue statement or omission made therein in reliance upon and
in conformity with written information furnished to the Company by or on behalf of any Placement Agent specifically for inclusion therein, it being understood and agreed that the only such information furnished by or on behalf of any Placement Agent
consists of the information described as such in Section&nbsp;7(b) hereof. This indemnity agreement will be in addition to any liability which the Company may otherwise have. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Placement Agent severally and not jointly agrees to indemnify and hold harmless the Company, each of its directors, each of its
officers who signs the Registration Statement, and each person who controls the Company within the meaning of either the Act or the Exchange Act, to the same extent as the indemnity from the Company to each Placement Agent set forth in paragraph
7(a) above, but only with reference to written information relating to such Placement Agent furnished to the Company by or on behalf of such Placement Agent specifically for inclusion in the documents referred to in the foregoing indemnity. This
indemnity agreement will be in addition to any liability which any Placement Agent may otherwise have. The Company acknowledges that there has been no information furnished in writing by or on behalf of the several Placement Agents for inclusion in
the documents referred to in the foregoing indemnity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Promptly after the receipt by any person in respect of which indemnification may be
sought pursuant to either Section&nbsp;7(a) or 7(b) above of notice of the commencement of any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand, such person (the &#147;<B>Indemnified
Person</B>&#148;) will, if a claim in respect thereof is to be made against whom such indemnification may be sought (the &#147;<B>Indemnifying Person</B>&#148;) notify the Indemnifying Person in writing of the commencement thereof; provided that the
failure so to notify the Indemnifying Person (i)&nbsp;will not relieve it from any liability that it may have under this Section&nbsp;7 unless and to the extent that it did not otherwise learn of such action and such failure results in the
forfeiture by the Indemnifying Person of substantial rights and defenses and (ii)&nbsp;will not, in any event, relieve the Indemnifying Person from any obligations to an Indemnified Person other than the indemnification obligation provided in
Section&nbsp;7(a) or Section&nbsp;7(b) above. The Indemnifying Person shall be entitled to appoint counsel of the Indemnifying Person&#146;s choice at the Indemnifying Person&#146;s expense to represent the Indemnified Person in any action, and any
others entitled to indemnification pursuant to this Section that the Indemnifying Person may designate in such action, for which indemnification is sought (in which case the Indemnifying Person shall not thereafter be responsible for the fees and
expenses of any separate counsel retained by the Indemnified Person or Indemnified Persons except as set forth below); provided, however, that such counsel shall be satisfactory to the Indemnified Person. Notwithstanding the Indemnifying
Person&#146;s election to appoint counsel to represent the Indemnified Person in an action, the Indemnified Person shall have the right to employ separate counsel (including local counsel), and the Indemnifying Person shall bear the reasonable fees,
costs and expenses of such separate counsel if (A)&nbsp;the use of counsel chosen by the Indemnifying Person to represent the Indemnified Person would present such counsel with a conflict of interest, (B)&nbsp;the actual or potential defendants in,
or targets of, any such action include both the Indemnified Person and the Indemnifying Person and the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it and/or other Indemnified Persons which are
different from or additional to those available to the Indemnifying Person, (C)&nbsp;the Indemnifying Person shall not have employed counsel satisfactory to the Indemnified Person to represent the Indemnified Person within a reasonable time after
notice of the institution of such action or (D)&nbsp;the Indemnifying Person shall authorize the Indemnified Person to employ separate counsel at the expense of the Indemnifying Person. It is understood and agreed that the Indemnifying Person shall
not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the reasonable fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons and that all such
reasonable fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for one or more of the Placement Agents and any of their affiliates, directors and officers and their control persons, if any, shall be designated
in writing by the Placement Agents, as applicable, and any such separate firm for the Company, its directors, its officers who signed the Registration Statement and its control persons, if any, shall be designated in writing by the Company. An
Indemnifying Person will not, without the prior written consent of the Indemnified Persons, settle or compromise or consent to the entry of any judgment with respect to any pending or threatened claim, action, suit or proceeding in respect of which
indemnification or contribution may be sought hereunder (whether or not the Indemnified Persons are actual or potential parties to such claim or action) unless such settlement, compromise or consent includes (i)&nbsp;an unconditional release of each
Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability arising out of such claim, action, suit or proceeding; and (ii)&nbsp;does not include a statement as to, or an admission of, fault,
culpability or a failure to act, by or on behalf of any Indemnified Person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) In the event that the indemnity provided in paragraph
(a)&nbsp;or (b) of this Section&nbsp;7 is unavailable or insufficient to hold harmless an Indemnified Person for any reason, then each Indemnifying Person agrees to contribute to the aggregate losses, claims, damages and liabilities (including legal
or other expenses reasonably incurred in connection with investigating or defending the same) (collectively, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;<B>Losses</B>&#148;) to which the Company and one or more of the Placement Agents may be subject in such proportion as is appropriate to reflect the relative benefits received by the
Company, on the one hand, and the Placement Agents, on the other, from the offering and sale of the Shares pursuant to this Agreement. If the allocation provided by the immediately preceding sentence is unavailable for any reason, the Company and
the Placement Agents severally shall contribute in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company, on the one hand, and the Placement Agents, on the other, in connection with
the statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. Benefits received by the Company shall be deemed to be equal to the total net proceeds from the sale of the Shares (before deducting
expenses) received by it as set for the on the cover page of the Final Prospectus Supplement, and benefits received by the Placement Agents shall be deemed to be equal to the total Placement Fee. Relative fault of the Company, on the one hand, and
the Placement Agents, on the other, shall be determined by reference to, among other things, whether any untrue or any alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information
supplied by each such party, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement or omission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) In no case shall any Placement Agent (except as may be provided in any agreement among Placement Agents relating to the offering of the
Shares) be responsible for any amount pursuant to this paragraph 7(e) in excess of the Placement Fee. The Company and the Placement Agents agree that it would not be just and equitable if contribution were determined by pro rata allocation or any
other method of allocation which does not take account of the equitable considerations referred to above. Notwithstanding the provisions of this paragraph 7(e), no person guilty of fraudulent misrepresentation (within the meaning of
Section&nbsp;11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section&nbsp;7, each person who controls a Placement Agent within the meaning of either
the Act or the Exchange Act and each director, officer, employee and agent of a Placement Agent shall have the same rights to contribution as such Placement Agent, and each person who controls the Company within the meaning of either the Act or the
Exchange Act, each officer of the Company who shall have signed the Registration Statement and each director of the Company shall have the same rights to contribution as the Company, subject in each case to the applicable terms and conditions of
this paragraph 7(e). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The remedies provided for in this Section&nbsp;7 are not exclusive and shall not limit any rights or remedies
which may otherwise be available to any Indemnified Person at law or in equity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Payment of Expenses</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, will pay or reimburse
if paid by any Placement Agent all costs and expenses incident to the performance of the Company&#146;s obligations under this Agreement and in connection with the transactions contemplated hereby, including but not limited to costs and expenses of
or relating to (i)&nbsp;the preparation, printing, filing, delivery and shipping of the Registration Statement, any Issuer Free Writing Prospectus, the Pricing Disclosure Package and the Final Prospectus Supplement, and any amendment or supplement
to any of the foregoing and the printing and furnishing of copies of each thereof to the Placement Agents and dealers (including costs of mailing and shipment), (ii) the registration, sale and delivery of the Shares including any stock or transfer
taxes and stamp or similar duties payable upon the sale or delivery of the Shares and the printing, delivery, shipping of the certificates representing the Shares, (iii)&nbsp;the fees and expenses of any transfer agent or registrar for the Shares,
(iv)&nbsp;fees, disbursements and other charges of counsel for the Company, (v)&nbsp;listing fees, if any, for the listing or quotation of the Shares on Nasdaq, (vi)&nbsp;fees and disbursements of the Company&#146;s auditor incurred in delivering
the letters described in Section&nbsp;4(f) hereof, and (vii)&nbsp;the costs and expenses of the Company in connection with the marketing of the Offering and the sale of the Shares to prospective Investors including, but not limited to, those related
to any presentations or meetings undertaken in connection therewith. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company agrees with the Placement Agents to pay (directly or by reimbursement) the
costs and expenses of the Company in connection with the marketing of the Offering and the sale of the Shares to prospective Investors including, but not limited to, those related to any presentations or meetings undertaken in connection therewith.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) It is understood that except as provided in this Section&nbsp;6, Section&nbsp;7 and Section&nbsp;8 hereof, the Placement Agents shall
pay all of their own expenses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Notices</U>. All notices and other communications under this Agreement shall be in writing and shall
be deemed to have been duly given if mailed or transmitted and confirmed by any standard form of communication, and: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">If to the Placement Agents:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Citigroup Global Markets Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">388 Greenwich Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">New York, NY 10013</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Facsimile: (646) <FONT STYLE="white-space:nowrap">291-1469</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Attention: General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">with a copy to:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cooley LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">55 Hudson Yards</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">New York, NY 10001</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Facsimile: (212) <FONT STYLE="white-space:nowrap">479-6275</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Attention: Daniel I. Goldberg, Esq.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">If to the Company:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Lexicon Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">8800 Technology Forest Place</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Woodlands, TX 77381</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Attention: Brian Crum</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">with a copy to:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Facsimile: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">281-863-8010</FONT></FONT> Vinson&nbsp;&amp; Elkins LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1001 Fannin Street, Suite 2500</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Houston, Texas 77002</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Facsimile: (713) <FONT STYLE="white-space:nowrap">615-5861</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Attention: David Oelman</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any party hereto may change the address for receipt of communications by giving written notice to the others.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Governing Law</I>. This Agreement and any claim, controversy or dispute arising under or relating to this Agreement shall be governed
by, and construed in accordance with, the laws of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Submission to Jurisdiction</I>. The Company hereby submits to the exclusive
jurisdiction of the U.S. federal and New York state courts in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. The Company waives any
objection which it may now or hereafter have to the laying of venue of any such suit or proceeding in such courts. The Company agrees that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding
upon the Company and may be enforced in any court to the jurisdiction of which Company is subject by a suit upon such judgment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<I>Waiver of Jury Trial</I>. Each of the parties hereto hereby waives any right to trial by jury in any suit or proceeding arising out of or relating to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Persons Entitled to Benefit of Agreement</U>. This Agreement shall inure to the benefit of and be binding upon the parties hereto and
their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Placement Agent referred to in Section&nbsp;7 hereof. Nothing in this Agreement is intended or shall be construed
to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Shares from the Company shall be deemed to be a successor merely by reason of such
purchase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Counterparts</U>. This Agreement may be signed in counterparts (which may include counterparts delivered by any standard
form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.
<U>Survival</U>. The respective indemnities, rights of contribution, representations, warranties and agreements of the Company and the Placement Agents contained in this Agreement or made by or on behalf of the Company or the Placement Agents
pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of and payment for the Shares and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by
or on behalf of the Company or the Placement Agents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Certain Defined Terms</U>. For purposes of this Agreement, except where
otherwise expressly provided, the following terms shall have the meanings indicated. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>affiliate</B>&#148; shall
have the meaning set forth in Rule 405 under the Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Base Prospectus</B>&#148; shall mean the prospectus
referred to in paragraph 1(a) above contained in the Registration Statement at the Effective Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>business
day</B>&#148; shall mean any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions or trust companies are authorized or obligated by law to close in New York City. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Code</B>&#148; shall mean the Internal Revenue Code of 1986, as amended, and applicable regulations promulgated
thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Commission</B>&#148; shall mean the Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Effective Date</B>&#148; shall mean each date and time that the Registration Statement and any post-effective
amendment or amendments thereto became or become effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Execution Time</B>&#148; shall mean the date and time that this
Agreement is executed and delivered by the parties hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Final Prospectus Supplement</B>&#148; shall mean the
prospectus supplement relating to the Shares that was first filed pursuant to Rule 424(b) after the Execution Time, together with the Base Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Free Writing Prospectus</B>&#148; shall mean a free writing prospectus, as defined in Rule 405. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Initial Sale Time</B>&#148; shall mean 8 a.m. (Eastern time) on the date of this Placement Agency Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuer Free Writing Prospectus</B>&#148; shall mean an issuer free writing prospectus, as defined in Rule 433. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Preliminary Prospectus Supplement</B>&#148; shall mean any preliminary prospectus supplement to the Base Prospectus
which describes the Shares and the offering thereof and is used prior to filing of the Final Prospectus Supplement, together with the Base Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Pricing Disclosure Package</B>&#148; shall mean (i)&nbsp;the Base Prospectus, (ii)&nbsp;the pricing information set
forth in Exhibit B hereto, (iii)&nbsp;the Issuer Free Writing Prospectuses, if any, identified in Annex A hereto and (iv)&nbsp;any other Free Writing Prospectus that the parties hereto shall hereafter expressly agree in writing to treat as part of
the Pricing Disclosure Package. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Prospectus Delivery Period</B>&#148; shall mean such period of time after the
first date of the public offering of the Shares as in the opinion of counsel for the Placement Agents a prospectus for the Shares is required by law to be delivered (whether physically or through compliance with Rule 172 under the Act or any similar
rule) in connection with the offering or sale of Shares by any Placement Agent or dealer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration
Statement</B>&#148; shall mean the registration statement referred to in paragraph 1(a) above, including exhibits and financial statements, as amended on each Effective Date and, in the event any post-effective amendment thereto becomes effective
prior to the Closing Date, shall also mean such registration statement as so amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Rule 158</B>&#148;,
&#147;<B>Rule 163</B>&#148;, &#147;<B>Rule 164</B>&#148;, &#147;<B>Rule 172</B>&#148;, &#147;<B>Rule 405</B>&#148;, &#147;<B>Rule 415</B>&#148;, &#147;<B>Rule 424</B>&#148;, &#147;<B>Rule 433</B>&#148;, &#147;<B>Rule 456</B>&#148; and &#147;<B>Rule
457</B>&#148; refer to such rules under the Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subsidiary</B>&#148; shall have the meaning set forth in Rule
405 under the Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Recognition of the U.S. Special Resolution Regimes</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In the event that any Placement Agent that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the
transfer from such Placement Agents of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement,
and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event
that any Placement Agent that is a Covered Entity or a BHC Act Affiliate of such Placement Agent becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Placement
Agent are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Section&nbsp;15: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>BHC Act Affiliate</B>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in
accordance with, 12 U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Covered Entity</B>&#148; means any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b);
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b);
or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;
382.2(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Default Right</B>&#148; has the meaning assigned to that term in, and shall be interpreted in
accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>U.S. Special Resolution
Regime</B>&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Compliance with USA Patriot Act</U>. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. <FONT
STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Placement Agents are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may
include the name and address of their respective clients, as well as other information that will allow the Placement Agents to properly identify their respective clients. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Amendments or Waivers</U>. No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure
therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto or thereto as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Electronic Signatures</U>. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by
the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have
been duly and validly delivered and be valid and effective for all purposes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Headings</U>. The headings herein are included for
convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation of, this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing correctly sets forth your understanding of our agreement, please so
indicate in the space provided below for that purpose, whereupon this letter and your acceptance shall constitute a binding agreement among the Company and the Placement Agents. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LEXICON PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey L. Wade</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jeffrey L. Wade</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer&nbsp;&amp; EVP Corp&nbsp;&amp; Admin Affairs</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Placement Agent Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">confirmed and accepted as of the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">date first above written. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CITIGROUP GLOBAL MARKETS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey B. Rosichan </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Jeffrey B. Rosichan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Placement Agent Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Issuer Free Writing Prospectuses </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Purchase Agreement </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pricing Information </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Number of Shares: 20,312,500 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Offering Price per Share: $3.20 </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>d68225dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEXICON ANNOUNCES OFFERING OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Woodlands, Texas, December</B><B></B><B>&nbsp;11, 2020</B> &#150; Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it had entered into
a securities purchase agreement with certain institutional investors providing for the purchase and sale, in a registered direct offering, of 20,312,500 shares of its common stock, par value $0.001 (the &#147;Common Stock&#148;), at a price of $3.20
per share, for aggregate gross proceeds to the Company of $65,000,000 before deducting fees to the placement agent and other estimated offering expenses payable by the Company. The transaction is expected to close on December&nbsp;16, 2020, subject
to satisfaction of customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The investors in the registered direct offering were Artal International S.C.A., an affiliate of Invus,
L.P., and BVF Partners L.P. and certain affiliates of BVF Partners L.P. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc. is acting as placement agent for the offering on a
&#147;reasonable best efforts&#148; basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Common Stock described above is being offered by the Company pursuant to a &#147;shelf&#148; registration
statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> which was originally filed with the Securities and Exchange Commission (the &#147;SEC&#148;) on November&nbsp;7, 2019, and was declared effective on November&nbsp;18, 2019 (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-234568).</FONT> A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC&#146;s website at http://www.sec.gov or may be
obtained from: Citigroup Global Markets Inc., c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-831-9146.</FONT></FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press
release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of any such state or other jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Lexicon Pharmaceuticals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients&#146; lives. Through its Genome5000<SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP> program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases.
Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising
drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains
&#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements, including, without
limitation, statements about the completion and timing of the offering, are based on management&#146;s current assumptions and expectations and involve risks, uncertainties and other important factors, including Lexicon&#146;s ability to meet its
capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of LX9211, sotagliflozin and its other potential drug candidates on its anticipated timelines, achieve its operational
objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of
these risks, uncertainties and other factors may cause Lexicon&#146;s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is
contained under &#147;Risk Factors&#148; in Lexicon&#146;s filings with the Securities and Exchange Commission, including its annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019 and under the
heading &#147;Risk Factors&#148; in the final prospectus supplement related to the proposed public offering of common stock to be filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information, future events or otherwise. </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Inquiries: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chas Schultz </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Director, Corporate Communications and
Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon Pharmaceuticals </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(281) <FONT
STYLE="white-space:nowrap">863-3421</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cschultz@lexpharma.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>d68225dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical
company with a mission of pioneering medicines that transform patients&#146; lives. We are devoting most of our resources to the research and development of our most advanced drug candidates: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.
We identified the target of LX9211, adapter-associated kinase 1, or AAK1, in our target discovery efforts as a promising approach for the treatment of neuropathic pain, and identified LX9211 and another development candidate in a neuroscience drug
discovery alliance with Bristol-Myers Squibb from which we hold exclusive development and commercialization rights. In preclinical studies, LX9211 demonstrated central nervous system penetration and reduction in pain behavior in multiple models of
neuropathic pain, and has been demonstrated not to affect opiate pathways. We have reported <FONT STYLE="white-space:nowrap">top-line</FONT> results from two Phase 1 clinical trials of LX9211, and are now conducting a Phase 2 clinical trial of
LX9211 in diabetic peripheral neuropathic pain and preparing to initiate a second Phase 2 clinical trial of LX9211 in post-herpetic neuralgia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart
failure, in support of which we reported positive results from two outcomes studies involving approximately 10,500 and 1,200 patients, respectively, with primary endpoints evaluating a composite of total cardiovascular death, hospitalizations for
heart failure and urgent visits for heart failure. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We are also developing sotagliflozin as a treatment for type&nbsp;1
diabetes, in support of which we completed a Phase 3 program involving approximately 3,000 patients with type 1 diabetes. The FDA has issued a complete response letter regarding our application for regulatory approval to market sotagliflozin for
type 1 diabetes in the United States and has confirmed that position in denying two appeals of the complete response letter. Sotagliflozin has been approved in the European Union for use as an adjunct to insulin therapy to improve glycemic control
in adults with type 1 diabetes and a body mass index <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 27 kg/m2, who could not achieve adequate glycemic control despite optimal insulin therapy, but has not yet been commercially launched. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are conducting preclinical research and development and preparing to conduct clinical development of compounds
from a number of additional drug discovery and development programs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2020, we completed the sale of our
XERMELO<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (telotristat ethyl) product and related assets to TerSera Therapeutics LLC, or TerSera. We commercially launched XERMELO following regulatory approval in the United States in February
2017 for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults inadequately controlled by SSA therapy. In connection with the sale, TerSera assumed responsibility for the continued development of XERMELO as a
treatment for biliary tract cancer, currently in a Phase 2 clinical trial. We are eligible to receive development, regulatory and sales milestone payments from TerSera of up to an aggregate of $65&nbsp;million for the development and
commercialization of XERMELO in patients with biliary tract cancer and <FONT STYLE="white-space:nowrap">mid-teens</FONT> percentage royalty payments from TerSera on net sales of XERMELO in biliary tract cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sotagliflozin, XERMELO and compounds from a number of additional drug discovery and development programs originated from our own internal drug
discovery efforts, and LX9211 and other compounds targeting AAK1 originated from our collaborative neuroscience drug discovery efforts with Bristol-Myers Squibb. These efforts were driven by a systematic, target biology-driven approach in which we
used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the
corresponding human genes as potential drug targets. We have identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are working both independently and through strategic collaborations and alliances with
third parties to capitalize on our drug target discoveries and drug discovery and development programs. We seek to retain exclusive or <FONT STYLE="white-space:nowrap">co-exclusive</FONT> rights to the benefits of certain drug discovery and
development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians. We seek to collaborate with other pharmaceutical and
biotechnology companies with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States or commercialization in the
United States for indications treated by primary care physicians, or when the collaboration may otherwise provide us with access to expertise and resources that we do not possess internally or are complementary to our own. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon Pharmaceuticals was incorporated in Delaware in July 1995, commenced operations in September 1995 and was listed on The Nasdaq Global Select Market in
April 2000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>7
<FILENAME>d68225dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 99.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related to regulatory approval of our drug candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on our ability to gain alignment with the FDA and other regulatory authorities on our regulatory strategy for sotagliflozin in heart failure.
If we fail to effectively gain such alignment, our business will suffer and our stock price will likely decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have reported
positive results from two outcomes studies of sotagliflozin involving approximately 10,500 and 1,200 patients, respectively, with primary endpoints evaluating a composite of total cardiovascular death, hospitalizations for heart failure and urgent
visits for heart failure. In connection with the early <FONT STYLE="white-space:nowrap">close-out</FONT> of the studies, the primary endpoints were modified so that, among other things, the events of cardiovascular death, hospitalizations for heart
failure and urgent visits for heart failure were determined by clinical investigators rather than by independent adjudication. We cannot offer any assurances that the FDA and other regulatory authorities will accept the determination of such events
without independent adjudication or will not raise other concerns relating to the early <FONT STYLE="white-space:nowrap">close-out</FONT> of the studies. Should the FDA or other regulatory authorities require independent adjudication of such events
or otherwise object to our strategy of seeking regulatory approval of sotagliflozin in heart failure on the basis of the studies, as closed out early, our business and financial condition could be materially harmed and we may be more heavily
dependent on the success of our other drug programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related to our relationships with third parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on our ability to establish a strategic collaboration for the further development and commercialization of sotagliflozin in heart failure.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our existing resources and infrastructure are insufficient for the commercialization of sotagliflozin for heart failure. Although
we seek to collaborate with another pharmaceutical or biotechnology company or companies under terms which would enable reliance on their resources and infrastructure, in whole or in part, for those commercialization efforts and provide additional
funding to support our own activities in support of such efforts, including seeking regulatory approvals, we may be unable to successfully enter into any such collaborative arrangement on reasonable terms, or at all. If we are unable to enter into
any such collaborative arrangement, or if we are otherwise unable to raise sufficient additional capital, we will minimally require substantial additional resources to pursue and may elect or be forced to forego the further development and
commercialization of sotagliflozin in heart failure. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>lxrx-20201211.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 12/12/2020 1:23:59 AM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:lxrx="http://www.lexpharma.com/20201211"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.lexpharma.com/20201211"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20201211_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20201211_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>lxrx-20201211_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 12/12/2020 1:23:59 AM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>lxrx-20201211_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 12/12/2020 1:23:59 AM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="lxrx-20201211.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g68225dsp1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g68225dsp1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M6&=+5@I/S94@MUX'?O2]W0KWU>Y!8ZKK%Y\.H]72[B6_\EYF9X<J0-W&!C'
M'--J*G82E)T^;J;'A:^N-3\,:=>W3AYYX@[L !D_05$U:32+IMRBFR36]9CT
M.SCN9+:XN \JQ;8$W,,]_I1&/,[#E+E5S3%24% !0 4 5M0LHM2TZXLIQF*>
M,QM]"*:=G<35U8XKP?KC:5X6U*QO\FYT-VC*]W7)V ?4\#\*UG&\DUU,*4N6
M+3Z$7B6TU#0? \%S#J-Q;7OFJUQY3 "1Y'R^>,\$\8/040:E*UA5$X0NF7_'
M3ZA9)I-S8ZE/ TEY%;M$&_=MG/)QSV]>E*G9W3156ZLTROXFCU#PU=Z;K%OJ
M]Y/YMVD-Q#,X,;JWHH&%_"G"TKJPJEX-23':UKT5CXMN+77Y;NUTOR4^RO$7
M6-F/WBQ3G.>/;%$8WC[NX2G:5I;#)]=-II-G:Z1K!O3J=_Y$-R[^8T"'&1SW
M';/K0HW>JV!SLDHO<T/$]A=:1H<NJZ3?W:W=F!(PEF:19E'4,I..F>F*F#3=
MF543C'FBS&TR]U+5?%MM'%JMU':7VF"Z9"P)BW'D)QCJ, D$XS5M)1VV9G%N
M4]]T:.E?;M%\?/HIU&XO+"XM#<H+E][1L&QP?SJ7:4+V+C>-3EOH)XB\_P 8
M?;]&TP(G]G.KM<O_ ,]QRJ+_ %)Z9Z41]RS8IWJ7C'H+X;U2;4/#T]GI:06>
MO0-B[CNMQ(?NY[MG%$HV=WL.$KQLMR?0)O$6KZ'!?C5(HYV+JT<MJ&0E6*\$
M$''%*7*G:PX<\E>YSO@R?Q%%)K<6GV-G,6OW\V:68HJ/WPN,D?C6E3ETN94G
M-7LNIZ).LD>C2K-)YDH@8.X&-QV\G':L%N=+^$Y?0/\ DD:?]>$O\FK27\0R
MC_"^14\(Z@VLZ!8Z)8W;6OV2WC-U(ORRD'HJ>GNWY>H<URMMDTI<T5%%OQ\;
MO3- @NK'4KNW,4L<159,[P3W)YS^-*E9NS15:\8W3%\=/J%G)I%S8:C/ TM[
M% 80V(VSDY..>W/-%.SNF@JW5FF5O$D.H>&[W3-6MM7O)_.NT@N(9G!C<,>R
M@87OTIPM)--"G>#4DR3Q!KJ:=XK^SZW)=VVCFW'D/"65'<GYMQ7GCL*48WCI
MN$Y\LK2V-OPQ-:3VER]CJS:C:M-F,O(7:(;1\I)YZYZ^M3*ZW1I3::T=S=J#
M0XZ^\(S3^/(=5B8+I\J*UTF?OR(<IQWY"G\*U4[0L8.G^\YNA9\<:9J>M:,-
M.TZU20O(KM(\H4+M.<8ZFE3:B[L=6,I*R*OB>RUW6[33$M]+1'M[E+F3?<+C
M*Y^48]?6G!QC>[%44I)619\7:5J.NZ%9QVMLJW,=U',T3R 8"YR,]*4)*+U'
M4BY15B<W.M+>7*W.AF[LYRK1A9XR8OE 96#$9&03D9ZTK1MN.\KZHY^Y\ W$
MMC<W5KY%GJ+7HO((5.8X\# 3.._7(&,UHJFMF9NCI=;FY?IK6O:))ILNFG3I
M+A?+FF>9'55_B*!22<C.,XJ%RQ=[FCYI1LU8SK31=5L/%]O?6^F*-.M[,62J
M9UW[0>&_^M5.2<;7U(49*=TM"_?:9J2^/;36;:U6>T2S-N_[P*P)8G(!Z]JE
M-<EBG&7M%)%!-*U_PYXGU"^TNT34M.U&3S9(/-6.2-O4%N.YJKQE%)Z-$\LX
M2;BKID6M^'=6UV\&J6%K_8NHQQLIE:<%YAC&TA,C\<_AZ$9*.CU03A*3NM&;
MF@/K%OH:17FC0VLEO'LC@AG!WXX&.RCZDU$K7T9I#F4=48OANQ\2: -19]'A
MG:\N6N,+=A=F>W3FKFXRMJ9TU.%]#2ED\1W5Q/(^DK#%]E>)(A=JVZ1B/F/0
M  #]34^ZNI?OM[%;3=.UFR\!-HCZ>INUA>!2)EV'=GYL]>,TVXN=R8QDJ?+8
MJV_A;5(M"TZ>V1;37]+C$:/O!CN$'5&QV/OT--S5WV8E3DHIK=%GQ78ZYX@\
M/PV4.F)%.9$DDWW"[5VG. 1US2@XQ=[CJ*4XVL+XHLM<UJ#2Q:Z6B/;7*73^
M9<+C*Y^48Z_6B#C&]V%12E:R+/BW3-1UO1+%;2V47,5U'.T4D@& N<C/2E!J
M+U'4BY15B=[G6X[Z;SM%:[LIU0JBS1YB.,,I#$ COD$TK1MN5>5]@\-Z"=*O
M=4OWABMFOY%86T7*Q*H('/3)))..*)2NDNPH0Y6WW.AJ#4* "@ H * "@ H
=* "@ H * "@ H * "@ H * "@ H * "@ H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g68225dsp1a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g68225dsp1a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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4T%0:!0 4 % !0 4 % !0 4 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>d68225d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lxrx-20201211.xsd" xlink:type="simple"/>
    <context id="duration_2020-12-11_to_2020-12-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2020-12-11</startDate>
            <endDate>2020-12-11</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2020-12-11_to_2020-12-11">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2020-12-11_to_2020-12-11"
      id="Hidden_dei_EntityCentralIndexKey">0001062822</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2020-12-11_to_2020-12-11">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2020-12-11_to_2020-12-11">2020-12-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2020-12-11_to_2020-12-11">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2020-12-11_to_2020-12-11">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2020-12-11_to_2020-12-11">000-30111</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2020-12-11_to_2020-12-11">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2020-12-11_to_2020-12-11">8800 Technology Forest Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2020-12-11_to_2020-12-11">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2020-12-11_to_2020-12-11">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2020-12-11_to_2020-12-11">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2020-12-11_to_2020-12-11">(281)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2020-12-11_to_2020-12-11">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="duration_2020-12-11_to_2020-12-11">Common stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2020-12-11_to_2020-12-11">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2020-12-11_to_2020-12-11">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="duration_2020-12-11_to_2020-12-11">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2020-12-11_to_2020-12-11">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2020-12-11_to_2020-12-11">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2020-12-11_to_2020-12-11">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2020-12-11_to_2020-12-11">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140179415064824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 11, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 11,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8800 Technology Forest Place<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(281)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M;3 (CPX:,<YX;+;^M]23V^K<6CF]DZ+5"N+<?[EAD?%U'.F,$\^^6S@IE2?
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M/[&\UDX:?^:+X3]>?P%02P$"% ,4    " ":BXM1!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( )J+
MBU'D"^NX[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( )J+BU&97)PC$ 8  )PG   3              "
M <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ FHN+47$ZDAY#
M!   4!   !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( )J+BU&#J:4#U $  #(&   -              "
M 8<,  !X;"]S='EL97,N>&UL4$L! A0#%     @ FHN+49>*NQS     $P(
M  L              ( !A@X  %]R96QS+RYR96QS4$L! A0#%     @ FHN+
M41PX9>H_ 0  / (   \              ( !;P\  'AL+W=O<FMB;V]K+GAM
M;%!+ 0(4 Q0    ( )J+BU$D'INBK0   /@!   :              "  =L0
M  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( )J+BU%E
MD'F2&0$  ,\#   3              "  < 1  !;0V]N=&5N=%]4>7!E<UTN
9>&UL4$L%!@     )  D /@(   H3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d68225d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d68225d8k.htm">d68225d8k.htm</File>
    <File>d68225dex101.htm</File>
    <File>d68225dex102.htm</File>
    <File>d68225dex51.htm</File>
    <File>d68225dex991.htm</File>
    <File>d68225dex992.htm</File>
    <File>d68225dex993.htm</File>
    <File>lxrx-20201211.xsd</File>
    <File>lxrx-20201211_lab.xml</File>
    <File>lxrx-20201211_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d68225d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d68225d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20201211_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20201211_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20201211.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20201211",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d68225d8k.htm",
      "contextRef": "duration_2020-12-11_to_2020-12-11",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d68225d8k.htm",
      "contextRef": "duration_2020-12-11_to_2020-12-11",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001193125-20-316016-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-20-316016-xbrl.zip
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M]_V+""!*\UG;',R;>2/H-Q][-9?$7B>U;NB-X4D_'OBG_P]02P,$%     @
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MYDE>5[A1=9+E-(W6[N RPM;)>3@KBB%]=9&,9TE_#!L.=U=P..1\X@M*8!#
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M@\ DIK-R6E2ID3_H+\GJF03+T'310:##2@X%*19>&6V95)P99N)"A+A1_=1
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MQ?#B-8N5=8T1I.*\2UD)#!%](? \X3,.%R7<"SU\<=>2PV_(S$!DX_S*9,
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MFY ?TY=UC8!N/%9W[3R:9#VR"C>&8UC=^1,-A(O/]#^;9>C2S75OF%?+>BU
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M$K _W"XSQB6.@>!?E(K>SBEC;I($;H?+)DR-]C:9:;,9W;6J.<V)F:9GA]G
M L)\OEGAK#QF3+[*JUI]FL;<4<\&=+U&[OJ'U94Y&6S>!Q.NM'/$K'<VA[&#
M]>VEX,=1,D#>D4@;.0:NT\)T0]AMQ.P^R).I4TNY'A$&X=1@>3O:;[K#RSXA
MN.@\FU8NZ295*$.CUQ]V5U@(BVP UO4W6EDVH)J:VLW<<'/<R(O;$;>Z$'_C
M[7&PVX_Y.+D<S:2<J;2LHE7BT@1'K)7<@=<H[V8PJ$UV<YC<P"WZ:=4L6-D1
M\R$4IPOZ,&R]5>>R(][(1?Z&J6#D<].[2R.MKC-P(:2%52"IS">Y[5T8PJ=#
M-VP1XTGF\ @ES+2"3K ;PJ5JR2H!4D_+%HG>!2[G'I1KUW.K*9#V\HNL+!0\
M#59IB^*6;"%.#AUWTY?G-5VC*SB;= YYSV=$':FE)"]]ND!(09AW.0A#$OC]
MC'X!JC$%)D8@E1)92M.=@-&"*&#@^G7R:*=Q(Z6&V_51XT+_/!P7 ?BD 6PC
M[X9\75.PHS6OFDSDV#GW5U<P3EV,Q^Y,2=!:IGT^ ^J(SE,P8\\)F\?!9RE%
M[0,$/ZKG:GOKI^OJUG J.+1<V!H(X%WR[Z0<%G#@]3Q6L6]/EHZ+2X9J@L'C
MN$ET;3+QI$^-3I*L1-!6":H6\"1\?AR=E9B *1_&!*R0"PHN;2.?Z"@D5*$!
MK*;A.!NEM@YU]XLIX8?L/G<"NP)B[.9&!P&=("X%0J5?L 2!EKHY=TM# +'/
MV0!+H-1II2.M*501N6KPIJ>\X0#BGPJ[D-K"A)UP;;<OJRMN8RQ8FS%K.!V3
M_"#8N*JB!;(=,V-TE2/D*4UJ2>VNBY*J:&%Z25$A3R0U$.LY\>SSX5BRWSN(
M9.[ NZ1.LSG@4M$NT&+ 6)YJ^+L1:TZTZP55)'"B7+V ;$.TQZ*NH*!_&BDK
M<V/(6&([H7;EG1T-&<PER7;<V[OR$9]E1A\[SZ=-B+UF?1KA8.T;X$/"A(QS
M(%L#H35U 'TI@M9*!9"@1:E5'M*;7F@:+!>%UE9&+J8[QY6-7FY5"_A\.@>>
MPPGQO.Y'NV+%?N]X_Z1W1W[]I?*[PW;VB^F!Z,F9X)UEOSJL<&-HZQW':2VX
MH6B?O?LG&KOM<3!_^]F3AYPU/:%FE*:7J.&YY'F?:6>%4)O1)AG2>7L>'\'U
M#JQ[VZN!W!3.&]["W+5RE_30\^-Y+WLC3.9%)$O'VK#HTR36)0K)B,Z-3W[1
MF,7JBGN5GU T29-<HZ)MG\6UN8@4G4XG_=3Y7U"R3@D199+=&TJ^E$"JHH?;
M#]?ZR(\'^)\)"92U0NA-3KGKRW&,1WN&X^*8ZO:SIX^7HH'5E;E$$%D:P%O=
MFN%; E$WZBX#T@C#<OD/7A+;T0PXDWJF4+:1&4"L:NZ)H$V#93%5M#"'Y4)#
M"7XT2Y1I?+"U,4RNM/:.\&=N2($CODRR"TX^-L7TBV8A?.O"HZLZNSI=?_J_
M[ @%=3*:E!VV5W.+_BU'8TXTA0")0*X?!G:]<.6G<"^8E9.?R2\KAPT(]SK+
MT1HD)L$/4XF:=;(22U3<&:S+<=,QR?RZ61+5@$KLJ*9%,A57U4&*(5=(0_2O
M);)?#&H"VP3>Q6]I$!CP;"W0118FIPI(*V'LTE(6DWA)*D16TY<7&X:T$T</
MGSW9IO\^PHL>/GNZ]=JK',.TT:N,U+*O3&;.ES9G!S2K"[D;T00[DWRU85[H
MH/3<PZWMM63=3@R?$-0HYI*/"'T]"UB#]V#W71P O1>^VC$5@[+9A/,A!!P,
MP#%@Q$R5UM65H-+R?82+&6CWNBP^N:*M=U6FH$\/I5#_D&O+J#.RQ,(<NIU4
M:F"L\5=2LB-7(\^K8E?R/"F'Q0]5+^HH-36RY,.@T;9:-%^%Q\\MS<'I=T'[
MB6_OXO9]5ZT1U.58_ H 2-;$L/1LN\2IK=Q'98)\%R>CD+@HY"710ZM">*CG
M?64WYX\+&MO>_NEZN[LCQ<9E#]C-QFY1EK.IJV--W[U&S1UT6W_(K@\J-YSB
M^5*U/?!VCC+CY=)IC=,G?,K/TL9)[MU3BU])X21LZB@"U3!DCB,F7*$%_6CI
M>3(>+1Q%JSY^Y6M.%;.R<KG0B>]_%G.^M']\9UY(5S#-F>=4]X'C7-ID!!5$
MG[ _TXB@#83%T5DVPAIR2)VHD(15Q-P]R'OR*@W]F-,"U<T!YI]1HU90Z:S-
MHYA8*0K&F '.XJ/RGEHR*J'(&6[T%(1;)H6,&^#_D2$."T?P0]1('N9NB/XE
M)HF+SY71L)A@Z9^!\82:F)^G,QLE4<O6W;&AI3BH!CE6[4<A+86!, J"YN8@
MDD9@4NW-VL.Q[JA;01;]L1:.E!&U0Y#F#CX>@<$C&:EJNW47R)82=R[I;/-D
M,WHK*R2G'^0C;NB JV&)P^6)-;975T)S^>WN42]PL=*C_QXIZ\#'[&QM;[F9
M"_K?R\P$.4U?+J>+X// <R/895;:75-CI*^828>L?U=R._80S]@2X%SZ,X>#
M1H /Z),<!:*"%U#>[WB&SL35%:&S./J4#3[U$]M58P$M+I$0NK2SLQDI3ZPM
M=F'KL-0+4I;FN))Q)R-7VCW3WA%#1H>Z9%2DPX%Z_4PWTG:K3X%*N@(U<SP*
M#O!E;M3OAG:DI$ASPN ]:)_BB/U0Y"D*1#*LN/GTI>GL8-SZ#5$Q3ZV,_9H3
MI,3X_VO&'F=4CZA3^S2A98--1&3NIS2=<J1W:#HG=E64WF5O.8]0^8&%]IA.
MVYXI;(4>. H%T=*,_=)(-)NK=82*LBUM4TD629?6'#AKU<_<A:/VCZ;GQ($O
M$"[T#;-CW^A HMZI^"\D;638'32CBHE-AW' "^?01E#CJ%FL3H+G6E*":M&M
MKIAB=*["8\=H8A/*X\Q%IS(D93_#&"9)S&LA52%5=CF%.^?&+>Q;I50(V[-,
M0;Q[.LB"!P=J('F*?<EI:XY]0F@STG)**,1TH/?4U"Z)4\WT*PE?^P2QJIY1
M*FE(,XH\EU^5-EP<UWK,8X6DL4U7>6\T,U20@ (APFMOC6PCT)YD+@#;I\"G
M9$0N5Z'!91\(ZVJ$*2C&-G45%QJI R@,RLRA6XJZ@/6J8BM<),#)?;!-H8I8
MK&E;0]?E'\#]HY2\'=I_!-O\4I8I]]U*2M&2)?>\BOS?-@^=(.ZE+SN++2UX
MQI)1WE$MI<9T7M/CQ;%;LY,<0A BD1Q :0'# 19@5'X'1QA?4',>0^ZD?DQ8
MVY7TF,8% ;!Z LJ0OE(>RF%<>,TX362[&YF_\[-!@8\%1]SI=F &R90Z"==H
M 0.D$>I(0DJ;0(W<+?X@D&_9TOIM2?W%DI-C[*#6,^"JNY+ZJ;5G?3D3C:2#
MHM0N&2MT\59R9Z,WY0S$J(%;-13R-RE: KKC[QA"A3>^(TS5"9>3<2$(\NC5
M=9JZ/"9T!%*^B-.UZ;D&9&8M(#",<$#HF$Z'Q,: I#%&U$R.YV(& ND:4(L@
M1C!?K:[LBZ[()^T8TY8NH]<%%BM9)"X-N^U)_KT5EO/<97!0JN)F&0 OYF%5
M%X+AN[/=8S'_2LX!&1+0P,<?FI/2/H(J?DT< Q6 :LIY:!P:D,%W9<DWQ$R7
MN+BS4_(#>P=W?GH'[U!3DOY'(*H-QO^&>26Q=0&NKLQ7"]7_5SD'8!5X ,,G
M?5//7JO1AX=KX3VNV 0O2@T[D;JH"G)?$(FZAJ'1(=)!B@3!'6I_];@ZPJYV
MDI\K(?#K4Y2I,^ X/DGE\&UOMPG8ZW[ "4.1Z5<N0W0@5I/#WNP6,^#.8[YH
M;X;IM""*X&KD8>]23$WZ$^2W4PS=>+1,DSSX[[#B0V24;C,0#'E!+2G]^EP+
M3C3TZ";X@D@PJY;=0T1>BY=(VE)+]@V5O6)A0MFK[)."W8(A(5/7$-VB?5]=
M<4,T[L1NS.@N:KX)_#OKPW_W2VS$<T -'O\.I)"P1G9R!4S_14LY<_E\W>E:
MKCBRRR8MI$Q_(2T>:2?&*6K^SC?LCPI%T$AK3"Y _'*5,JDD(=FI13/SPO4]
M^;, Q2Y"T,J,*B-1XXS6*2RT;VGLLF2E)SF.57P:(CG%TRS5/]'<U?PB]H40
MXA"?&DMD3*SGUA[&(CRY+ >Z5YPR[MX87[?'D=MB?IM$ZFERP#_S5%+B:(^L
MBN(=L^)ED*58"]'Y\BW5.\6*XY*9R8/PSAD7D-<B5PC%1(]Z,KS(*F27G*I;
ME,&V4OC?^$S<9,@CS/N0@!$_0M?A59J456>,M*LC,-(C\F:NT2.)JEJ76HMM
M8!'].1=A_>R$]6T<B?5#-?:Y<QOQ;WE XW[<442-)#?96/=*_1;]H;M,5/>
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M=S/,[WJPM1V!U5ZE_]H4..X1PY)E$ (AX&<\W.E\QD[PC$0;%5[OUPL,YY
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MJ&5Z:.*$9"P=TRKY);>!Q';TTO>0[)H]!;\K4C_'ZH>(_BQ 'S IY>'SO??
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M[5A2^/7PS3_ARW>G']Z_^G]02P,$%     @ FHN+4?(TFG7R<@  >C$" !
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MH:4"[YSGSIA8T+,NTLD(S TXXNC.%?"0,AJ4Q2?<+'C^* 7MQ_N6L)6^TML
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MF3'0AY@2)%6/FZ#)5Z(B$Y);GR;*\LMB<ID&H3]A;Y0K!,$"7-(D)DRGGN<
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M52$(*,+!1PYWS ;V)+ER;IBE+U5E[-^H!%T7RCJB(P$7\$I0<D%;D.(JQQ(
M;C0R$M<M%22=)G)446!N:#ZLN6.$BF\3W7!3$ME'IB!CH;M;P\^COJ2)LSY#
M,N8&O(FV3<(ZK*X3%.D4KO]@CS  )$K>S)]WN+5_LA0T>]RHL_1S4IE[E!R*
M8#>IEPT'"B41-V?*I6"])2(-&P=^]$4VHU@V;*!48LFN+=3S$/QX$+1R[FD=
M8(<=&AI._83PGDS!49BU(2JF]F2YGHBC/3[IV)-N^@80XMDV5[)T1\.52<F;
M-%KMUEGK:G+MW26K841N.]0/1'OD%02!9,Z3G!%<'61!:ZL0ZI-96ZG ]!B\
MPJ?<A@K+3:P>C7N43W1]W>-GT])%FQM=*FC+:RC-8VQ_WWJISVOKER\DRC#6
M\OH*YRMV]+JJBG12IS:*OEP9(>7"/=!&6,NB13@>1EC,:_? 5IZ1M;='_;@%
MP-.-L78I[$G[E4X@$_V82!Q*$WJ(SL4R^&$3?;C$@0PXSQ#?>Q6R?K)PV=)D
M;<,09!L1D9'R01G"_I>:]!0@U"+258F12K<^)S:3&9&A(OPC12'(A_/I@-TX
MM.<5IX*=0L(;VQ4;8J4 %]NBH]A;0<W937NL8*F*8=: =PG,HZ^/F 6>N[F#
M-C=70"OYLZPRX\'N_M>G?DP9+FY8(%.3K!)'5\E>]O=Z"BLL\OHPS[&W)'LE
M#?+FI<FLO=T'?P]:%]^E1?X76^06#;W>60X3(AG=&T&<M%[65?4&7*R^^.@1
MCU-N4C5(S(8SP,^AV!3UB[4T=/CB -:,F*-BD7IJ_-DDX2I0JLEDQ9N6PXPP
M&IL;=LF*6;-DM%FUO^9-VX&)VW9GV[7PMITN:@<:WM9 R))@, LW#X;7LI8>
M2^L&<*5MU%?: JMOE&"^-Z_]S2-E !U);US$<3JB( QYV5SN;,"K:/QA^B-W
M"/+>.2#-BW_5959,?'X\!)??U_#VXQ_A[2]F8+Z5@@(CJ,VF'6<6VFW.$SZA
MK=ABH]9ZJR"H;+]GU'ZT.CB"3?6CPD$=7:(/(S'(@CXM(!@ZP_0SJ>-$FLB(
M&;/L]EH&O;*&0K&^QI9RJ1M):=VA.5!NMV\5#LD;+$P/H_[>/M;6(Q83_G7N
MF+5:!*SX/+&QY )]GU2CY*_HUTDQ0%X_2G""VT&-U#TJB3\5P))T#6U D</.
M>:&1:%.0&S/>IJ/<S75:YN).;MBD[%ARG8;%#9ZR7Q?*,I*$Y-\EU595[DG!
M\A+(E>>&A!6EBT%Z:AWAZ\<?L'V PU#9,GR%V, #9#DS"YJF5YL)M2%%Y"97
M4L;8:>VZ/@RQ,(!AU;ZY')>3N>"?3 Q:UZ/)[\*#OWO)!SOI?9K):?>+GP>Z
MH1V1:-[9A JZX.++@BJGT18( Q*)1:U[>'_P:]7G-BJ$< 3ENV\%+KB6,\M=
M5\LM5'TN2W">74J@4QM0P'8G,^GE022:KJ>S?\CVYH;I LB_LQSS+/#D -"Z
MSQ$8/BD2<!6'H"NRVD^*R%A2B4VA[PKF097:OVL'N!B.!,C315;YV!8"P^N2
MJ<V]E1MW(-I9W;.+;)_N/&KS.W6INUY#]+1^2U)"$@_II>?S!"^]-*6?^,':
M/<U#'BTZFD)S[4ZL2^Z=3)%R"Q$C*:>IS9?@45.%20V*><X5O>Y-_E-A[TD3
M!_3Y/U3*4M<(MGRS%$JVGIR\H0L2,3I+:HG7@M&O%58Z:VL>1PH7^YZ[)GO!
ML8]VE-G5DQB-W5M4PG4B@X6[5-H5M6$U:$#G729(.!!V*J6,.U.@*G/1-]$,
MG<:.#\7$5$K@\,F+QBB:QV^02:A;W=\UI)EYX'P5^GHE%=(*V?'TQBV,;DZ+
M"+\?80='OLHN4]-&@R-BP1^U:@2;"0PI^!8PAZTWHQ<2)70,5<S!-Q8^S\J2
MB.J8:6-LB-79(>8@K7U*WA=*0A-S_OT2BUD"'(#?/JF#&<=DGC6O?4-ZIC$_
MKJJ1;P>E-470(](G)$A;@H9<Q,PI(/ ]Q:3>Q('F,.EUSK1K],B[A=<W*D:#
MQ_?^ON/YZ:DM4=,URRF*@#,3W2 V8Y"\BD,:6='2;EGDXO22UPHAH(J8(.7:
MIX7DDLKH[?'[CX<!"<X@G117V\USD8TYS"LSBA%3+O5'&(JZ*1&\:Q.M_@)P
MUPV#RK7XF=NE:9E9!>YJ;#J1H58@TBN^"&VCT@$E 6IAB);N/(FV9\7?!:=-
M8NM@>$?:A W-NE6-T3 :IZW(8D??@$>4N6MZ&L>V]9P6\[B2V=NX\-^;(MZP
MPL^9KQJ%;=6945:W,DD;5.L-#]WF:M99/3*DP:'*8?5?M'S,+EH7S2VC>+@6
M<+@F\A0_+3"1!Z3=1+L$$S.;X.F8J%E !@L6(Q9LCDR*(+1EY3(X\ MJ94Z7
M+&_4^L?W'L83G_R()]Z41IU_CW#9=@SNBDIY.4CC0X9"W4\*-I=XY"RA'+A<
MK,$OT: LX5Y'?D7]-[=P1Q^NO$2G6'X<%K.%!C'Y<Q6:BH+)4XNX3JDI&R;]
M-%W?H7QNDZJQDOIU3CY3 (>\:DU$4[VN.(-EZLHG*?/A<+5JH1FH0LME5-P"
M8V.I/#W'?+%\!YTG<B7-GW!)2(08?N ^V6QFY\(+QW9!3V1!&WU[F[78'9&I
M:TS%-[&PS9FR?(SN/+>OS2J+;<W"LFK']Q8Y6@$?IV?"//9F.Z?6"1EHU'"/
M_IS#I.A#B5KE8\I'I23G ?!$*V4H[T4)2KAZR$IU8"5N=\*7-?J=[0AJAM"_
MX&[#"Z?2GH=XNVQN4#8QL7A@KA,9.]\2)0X'+X=P9431,'Q<$WXAFQ>"C-_]
MZ]G^WA[VC^J*NEPASCQ'DP'I;2]3/3;;#6H;\#[*$;><0'>?:S,O4P]:B:.R
M6"03+/+G/$3X/*.K\+WK2T%0Q#Z<5Z#M\:1B6]X2XPGT@Y,T&N8#CA7QFXNR
M:BU)]]O5,;]+&QJWUBFJCII\TSFZT_-.@AX=UAZW%)MTACE@L6CLI CVZOTP
MU&]GYC4=EO@R?>0,PCYW@2PYA.MXHLWGGEQFB-T@T_R\8;0[L#?+ ?-,+Y6T
MGC5_X=E9S*LXGT^JA$@LG"9Q'"05W)+I^FOI7P??W3IRKG&5&H;#=8.CLKV5
MBU&0EN! //'GB)<;^R@5*,TIY@4=,L1GV N^++ QE]@!=WR+<S3 $!7%P2TD
M\Y+(-ADSQI:QIDQHR1A#)K1CW+(QZLYM7/?MM=0V(X5HR"(=T[]SW;CUIF+Z
M?&S1YA%927<+D0,!+]$9C8 FQVJ0:7MN7TE1;CVR+2I+F]WJ"?&LD1@++A##
MOS*F1)@8$.)OBEU*N?FVW=JJ>>U<GG6WB&*I:+"X*[NJTUDEA6$U\0?Y>B8*
M>(]33'2,KG5OA0"DH)>+-:1R),O2TT)Q^C&1!>'IM"D:@=ZJ@8_)"O"5^-BL
M_DQE*(PV-YRG':]I2>8&_-6&N['"-7W@V]@=9LP9&Y,HK*08S9D%:PCC*1C@
M;=C,.W@_PBJT$Y$9^-J9*H/H U$V*SMLS>W;BBKHJ=-\D,HA!6"_5!#[S%D-
MK_;IB!>R?8RJ$BPW$T^3Z%*R6L$M)E<<^P,>I)#=&WT#V>8K>?55[^/J9TS2
M\*W5?@\ED-=L(!HP:<.V[2YANN+0AF!""6M$.34C&Q0:JY/ ,(B7O__N8[Z7
MZT4H;A-IVE/0:W9E1@1J@M%G]XM2%>P,1T,T<0BT0<K'IFA8^5,1:'C<*1\0
M.Y@A9FGD;/CLR^8&95PT6U",*-7FRSJN[\;SQ7FW!\'0#O$Z! @?[PVZM(6Y
MQ;XD;]&-&N)T2 -HPTDH;ZBW.8V0O&?H$FE3V(* X,BQ#7H)Z,C125DS&4%@
MP<'C>R+J8*[Q25<&8GH'Z)%Q<EF4=*N/TF'&I'SE?"*^Q9@SMHKP^+\Z./ST
M1W#XIE3OU;T(#M-]?ZY=AKAY#N?RLUIZ@7E0.6SD1//,%<$F7*&5C^P*(L;:
M,U.%W[0A#+ZDJYE$LCA_K/)A=N7E93Z5!R557.!3!14^^!."8RDU%Y3ZV-BT
MNAN&1[V0CGD-5O](O/RY;U\3K(A\S_&"-D.@+L+DW+UY)5UW"!G?&P_FQCS-
M5X;VS\YZ\F?3>VZ3]9&P#U,$1ZC1B*LW<V""MAA<I!/-SG,5Y?HLC>CTX=<5
M!^H- 1.&Y:=*RQ2>/>\2LU]4XCJ:=C%F&\SV^1UIKWQ1+EWM-=>'+Z;&\K17
M Q]I8)'?P$3\;/64LQ+625!_I1U1!ST2NI13"#-A7CQ41R;[P@9>[%J CYRA
MAQ7"4_F5 T36R6<87#TOV72DY_+N3!:&,9!J01EZ5DLE3Q@VY2]2'0R,!YZ:
M&ON3A8;^&K"A3MES!B-D-!=U-DL6VKAAX3C9#$J-RVM8ER-DA<4JQZ Y'(5+
MJN(5>()Y3P</'&>Z"-RCY7G66<YYJ";&8,TV65;-A8U@HO@19.<H+^7H:O2C
MFVG#D<<0B<H2!KR[E__%=D?;F3A,:F$]O*";M4$;V+HSLB"UJX<F @7>6)2^
M@S=,V@<$7/B*%U@DC+F:K>O 6I"M^S\8'7<B7Y&JO#OH/V9E6HL82,UJN2##
M<V@!ACX4!(,S/"+'_C.>1Y76;N_9PUT&7$Z9T',+/V]RFEU?- [.W4O+?UK2
M0IS;J:??)FS)&+VL87&><X,9T]"GFB$;G.0!].S2Q2(\XD1<E56?-# GL:\I
MGA5WQ<W*^<A!^ER&2P3"^*FNFIXK#M(<3:/13HM&AAIUHC9GY47=""-M/VR.
M0:0X3S!+8%4RLI(8O(/!<.7#(DIR$C)),%ZD,@_W%[@N,CDG#+1S.L]]A)L
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MD ROU!GACPVY0<-<%,ZA*GJX]W!K@(IXB/\SI:MDJQ IE.-]K/T1/N*9GN/
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M[HE##&SH[] D2/)/2CMC]_I%%'9PLV(0,/<S,@X/ORR^4CPAI12/?,$WL7N
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M[Q7??4K1?3ANGMA.QW_W(I%M@ZWLR&LUQ"P0"ABXO9(W-XXI8SF)3C$!<48
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M9,O7M+K//(%M=<I$IA3B$O<LHFMF:.O%YKG#[*(?Q?R[/H7>'FY0F60@KWT
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M;!1((IQ&*C<Q@4RAWUFR"&+[FQMPS5'$7V!-K1(<\I=:&=$L'S(K54>_I/#
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M>F9;DQR*JM42H)V2#P4)0SC2OA%E4O9XY#;15!"Q\!2OJ,_<+?'"KV(!!1(
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M37U1E7U:0A>.$GH"=(P?!O$U?F\Z%]6>N/[,]@Q;>#\Y!F\S6XQ@SDQW1?9
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M%=XM73?W4&X24'.<>3XIN<H6V-64BC.?<SD2HKY,7[1M<?X/VRB7P4%J[K#
M/,&YN6)>S/.(6/(W4$L! A0#%     @ FHN+4:_Q8.#$%0  DX8   T
M         ( !     &0V.#(R-60X:RYH=&U02P$"% ,4    " ":BXM1G!%V
MS=E>  "DSP$ $               @ 'O%0  9#8X,C(U9&5X,3 Q+FAT;5!+
M 0(4 Q0    ( )J+BU'R-)IU\G(  'HQ @ 0              "  ?9T  !D
M-C@R,C5D97@Q,#(N:'1M4$L! A0#%     @ FHN+48?9UN'/"0  62(   \
M             ( !%N@  &0V.#(R-61E>#4Q+FAT;5!+ 0(4 Q0    ( )J+
MBU&4X&L@I H  'P<   0              "  1+R  !D-C@R,C5D97@Y.3$N
M:'1M4$L! A0#%     @ FHN+440.1+)0"P  %B(  !               ( !
MY/P  &0V.#(R-61E>#DY,BYH=&U02P$"% ,4    " ":BXM1JN"*5F %  !W
M#@  $               @ %B" $ 9#8X,C(U9&5X.3DS+FAT;5!+ 0(4 Q0
M   ( )J+BU&=Z-708P,  "H,   1              "  ? - 0!L>')X+3(P
M,C Q,C$Q+GAS9%!+ 0(4 Q0    ( )J+BU&NH5/A7@8  $E$   5
M      "  8(1 0!L>')X+3(P,C Q,C$Q7VQA8BYX;6Q02P$"% ,4    " ":
MBXM1O=#'.+<$   )*P  %0              @ $3& $ ;'AR>"TR,#(P,3(Q
?,5]P<F4N>&UL4$L%!@     *  H <P(  /T< 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
